

1001 DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS
 1051 STRSGGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAGLQS
 1101 LPTHDPSPLO RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP
 1151 SPREGPLPAA RPAGATLERA KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
 1201 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG
 1251 LDVPV

L4 ANSWER 45 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:736403 HCAPLUS
 DOCUMENT NUMBER: 131:350249
 TITLE: Active vaccination against cancer
 INVENTOR(S): Agus, David B.; Scheinberg, David; Roberts, Wendy;
 Zelenetz, Andrew D.
 PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9957981	A1	19991118	WO 1999-US10065	19990507
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2330212	AA	19991118	CA 1999-2330212	19990507
EP 1075184	A1	20010214	EP 1999-921790	19990507
R: DE, DK, ES, FR, GB, IT, SE				
JP 2002514573	T2	20020521	JP 2000-547851	19990507
PRIORITY APPLN. INFO.:			US 1998-84870P	P 19980508
			WO 1999-US10065	W 19990507
IT 100630-38-4, Receptor (human MKN-7 cell gene c-erbB2 precursor protein moiety reduced)				
RL: PRP (Properties)				
(unclaimed protein sequence; active vaccination against cancer)				
RN 100630-38-4 HCAPLUS				
CN Receptor (human MKN-7 cell gene c-erbB2 precursor protein moiety reduced) (9CI) (CA INDEX NAME)				

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
 51 QGCQVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIHNO VRQVPLQRLR
 101 IVRGTQLFED NYALAVLDNG DPLNNTTPVT GASPGLREL QLRSLTEILK
 151 GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
 201 GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
 251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
 301 YNYLSTDVGS CTLVCPHNO EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
 351 REVRAVTSAN IQEFAGCKKI FGLAFLPES FDGDPASNTA PLQPEQLQVF
 401 ETLEEITGYL YISAWPDSLP DLSVFNLLQV IRGRILHNGA YSLTLQGLGI
 451 SWLGLRSLRE LGSGLALIHH NTHLCFVHTW PWDQLFRNPH QALLHTANRP
 501 EDECVGEGLA CHQLCARGHC WPGPTQCVN CSQFLRGQEC VEECRVLQGL
 551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVAHAH KDPPFCVARC
 601 PSGVKPDLSY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
 651 LTSIISAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRL LQETELVEPL
 701 TPGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
 751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL
 801 MPYGCLLDHV RENRGRIGSQ DLLNWCMIQA KGMSYLEDVR LVHRDLAARN
 851 VLVKSPNHVK ITDFGLARLL DIDETEHAD GGVPIKWMA LESILRRRFT

PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 EP 1480514 A2 20041201 EP 2003-714229 20030303
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 PRIORITY APPLN. INFO.: US 2002-360889P P 20020301
 WO 2003-US8278 W 20030303

IT 603223-63-8 603223-67-2

RL: PRP (Properties)

(unclaimed protein sequence; transgenic non-human mammals expressing
 CD8, tyrosine kinase receptor fusion transgene and uses for screening
 anti-cancer drugs and as cancer model)

RN 603223-63-8 HCAPLUS

CN 11: PN: US20030182668 SEQID: 11 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MALPVTALLL PLALLLHAAR PSQFRVSPLD RTWNLGETVE LKCQVLLSNP
 51 TSGCSWLFQP RGAAASPTFL LYLSQNKPKA AEGLDTQRFS GKRLGDTFVL
 101 TLSDFRRENE GYYFCSALSN SIMYFSHFVP VFLPAKPTTT PAPRPPTPAP
 151 TIASQPLSLR PEACRPAAGG AVHTRGLDFA CDIYIWAPLA GTCGVLLLSL
 201 VITLYCNHRN RRRVCKCPLE STMRRLLQET ELVEPLTPSG AMPNQAQMRI
 251 LKETELRKVK VLGSGAFGTV YKGIWIPDGE NVKIPVAIKV LRENTSPKAN
 301 KEILDEAYVM AGVGSPYVSR LLGICLTSTV QLVTQLMPYG CLLDHVREN
 351 GRLGSQDLLN WCMQIAKGMS YLEDVRLVHR DLAARNVLVK SPNHVKITDF
 401 GLARLLDIDE TEYHADGGKV PIKWMALESI LRRRFTHQSD VWSYGVTVWE
 451 LMTFGAKPYD GIPAREIPDL LEKGERLPQP PICTIDVYMI MVKCMWIDSE
 501 CRPRFRELVS EFSRMARDPQ RFVVIQNE DL GPASPLDSTF YRSLLDDDDM
 551 GDLVDAEEYL VPQQGFPCPD PAPGAGGMVH HRHRSSSTRS GGGDLTLGLE
 601 PSEEEAPRSP LAPSEGAGSD VFDGDLGMGA AKGLQSLPTH DPSPLQRYSE
 651 DPTVPLPSET DGYVAPLTCS PQPEYVNQPD VRPQPPSPRE GPLPAARPAG
 701 ATLERPKTLS PGKNGVVKDV FAFGGAVENP EYLTPQGGAA PQPHPPAFS
 751 PAFDNLYYWD QDPPERGAPP STFKGTPTAE NPEYLGLDVP V

RN 603223-67-2 HCAPLUS

CN 15: PN: US20030182668 SEQID: 15 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 TMRRLQETE LVEPLTPSGA MPNQAQMRIL KETELRKVKV LGSGAFGTVY
 51 KGIWIPDGEN VKIPVAIKVL RENTSPKANK EILDEAYVMA GVGSPYVSRL
 101 LGICLTSTVQ LVTQLMPYGC LLDHVREN RG RLGSQDLLNW CMQIAKGMSY
 151 LEDVRLVHRD LAARNVLVKS PNHVKITDFG LARLLDIDET EYHADGGKVP
 201 IKWMALESIL RRRRFTHQSDV WSYGVTVWEL MTFGAKPYDG IPAREIPDLL
 251 EKGERLPQP ICTIDVYMI VKCWMIDSEC RPRFRELVS EFSRMARDPQR
 301 FVVIQNE DL GPASPLDSTF YRSLLDDDDM DLVDAEEYLV VPQQGFPCPD
 351 APGAGGMVHH RHRSSSTRSG GGDLTGLLEP SEEEAPRSPL APSEGAGSDV
 401 FDGDLGMGAA KGLQSLPTH PSPLQRYSED PTVPLPSETD GYVAPLTCS
 451 QPEYVNQPDV RPQPPSPREG PLPAARPAGA TLERPKTLSP GKNGVVKDV
 501 AFGGAVENPE YLTPQGGAA PQPHPPAFSP AFDNLYYWDQ DPPERGAPP
 551 TFKGTPTAEN PEYLGLDVPV

L4 ANSWER 24 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:704074 HCAPLUS

DOCUMENT NUMBER: 139:375933

TITLE: Identification and characterization of mouse

ErbB2 gene in silico
AUTHOR(S): Katoh, Masuko; Katoh, Masaru
CORPORATE SOURCE: M & M Medical BioInformatics, Narashino, 275-0022,
Japan
SOURCE: International Journal of Oncology (2003), 23(3),
831-835
CODEN: IJONES; ISSN: 1019-6439
PUBLISHER: International Journal of Oncology
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 623591-00-4

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
(amino acid sequence; identification and characterization of mouse
ErbB2 gene in silico)

RN 623591-00-4 HCAPLUS

CN Receptor tyrosine kinase (mouse gene ErbB2) (9CI) (CA INDEX NAME)

SEQ 1 MELAAWCRWG FLLALLSPGA AGTQVCTGTD MKLRLPASPE THLDMLRHLY
51 QGCQVVOGNL ELTYLPANAS LSFLQDIQEV QGYMLIAHNR VKHVPLQRLR
101 IVRGTLQFED KYALAVLDNR DPLDNVTAA PGRTPEGLRE LQLRSLTEIL
151 KGGVLIIRGNP QLCYQDMVLW KDVLKNNQL APVDMDTNRS RACPPCAPTC
201 KDNHCWGESP EDCQILTGTI CTSGCARCKG RLPTDCCHEQ CAAGCTGPKH
251 SDCLACLHFN HSGICELHCP ALITYNTDTF ESMLNPEGRY TPGASCVTTC
301 PYNYLSTEVG SCTLVCPNN QEVTAEEDGTQ RCEKCSKPCA GVCYGLGMEH
351 LRGARAITSD NIQEFAGCKK IPGSLAFLPE SFDGNPSSGV APLKPEHLQV
401 FETLEEITGY LYISAWPESF QDLSVFQNL RIRGRILHDG AYSLTLQGLG
451 IHSGLGLSLR ELGSLGLALIH RNTHLCFVNT VPWDQLFRNP EQALLHSGNR
501 PEEACGLEGL VCNSLCARGH CWGPGPTQCV NCSQFLRGQE CVEECRVWKG
551 LPREYVRGKE CLPCEPECQP QNSSETCYGS EADQCEACAH YKDSSSCVAR
601 CPSGVKPDLS YMPIWKYPDE EGICQPCPIN CTHSCVDLDE RGCPAEQRAS
651 PVTPIIATVV GVLLPLIIVV VIGILIKRRR QKIRKYTMRR LLQETELVEP
701 LTPSGAVPNQ AQMRILKETE LRKLKVLGSG AFGTVYKGIW IPDGENVKIP
751 VAIKVLRENT SPKANKEILD EAYVMAGVGS PYVSRLLGIC LTSTVQLVTQ
801 LMPYGCLLDH VREHRGRLGS QDLLNWCVQI AKGMSYLEEV RLVRDLAAR
851 NVLVKSPNHV KITDFGLARL LDIDETEHYA DGGKVPIKWM ALESILRRKF
901 THQSDVWSYG VTVWELMTFG AKPYDGI PAR EIPDLLEKGE RLPQPPICTI
951 DVYIMIMVKCW MIDSECRPRF RELVSEFSRM ARDPQRFVVI QNEDLGPSSP
1001 MDSTFYRSL EDDDMGLEVD AEEYLVPQQG FFSPDPALGT GSTAHRHRS
1051 SSARSGGEL TLGLEPSEEE PRRSPLAPSE GAGSDVFDGD LAVGVTKGLQ
1101 SLSPHDL SPL QRYSEDPTLP LPPETDGYVA PLACSPQPEY VNQPEVRPQS
1151 PLTPEGPPPP IRPAGATLER PKTLPSPKNG VVKDVFAFGG AVENPEYLAP
1201 RAGTASQPHP SPAFSPAFDN LYYWDQNSSE QGPPSTFEG TPTAENPEYL
1251 GLDVPV

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

I4 ANSWER 25 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:590927 HCAPLUS

DOCUMENT NUMBER: 139:143920

TITLE: Binding peptides specific for the extracellular domain
of **ErbB2** and uses in diagnosis and treatment

INVENTOR(S): Krag, David N.; Pero, Stephanie C.; Oligino, Lyn

PATENT ASSIGNEE(S): University of Vermont and State Agricultural College,
USA

SOURCE: PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003061559	A2	20030731	WO 2002-US32947	20021015
WO 2003061559	C2	20040624		
W: AU, CA, JP				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
US 2003216309	A1	20031120	US 2002-272437	20021015
PRIORITY APPLN. INFO.:			US 2001-329183P	P 20011012
IT 569386-48-7				
RL: PRP (Properties)				
(unclaimed protein sequence; binding peptides specific for the extracellular domain of ErbB2 and uses in diagnosis and treatment)				
RN 569386-48-7 HCAPLUS				
CN 28: PN: WO03061559 SEQID: 28 unclaimed protein (9CI) (CA INDEX NAME)				

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
51 QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR
101 IVRGTQLFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK
151 GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
201 GSRGWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRTY FGASCVTACP
301 YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
351 REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
401 ETLEEITGYL YISAWPDSL PDLVFNQNLQV IRGRILHNGA YSLTLQGLGI
451 SWGLRLSLRE LGSGLALIIH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
501 EDECVGEGLA CHQLCARGHC WPGGPTQCVN CSQFLRGQEC VEECRVLQGL
551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVAHAHY KDPPFCVARC
601 PSGVKPDLISY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
651 LTSIVSAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRR LQETELVEPL
701 TPGGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL
801 MPYGCLLDHV RENRGRGSGQ DLLNWCMQIA KGMSYLEDVR LVHRDLAARN
851 VLVKSPNHVK ITDFGLARLL DIDETEHYAD GGKVPIKWMA LESILRRRFT
901 HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID
951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL
1001 DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS
1051 STRSGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAGLQSL
1101 LPTHDPSPLO RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP
1151 SPREGPLPAA RPAGATLERA KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
1201 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG
1251 LDVPV

L4 ANSWER 26 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:532483 HCAPLUS
DOCUMENT NUMBER: 139:83971
TITLE: Recombinant antigen from **Her2/neu**
for tumor immunotherapy
INVENTOR(S): Nelson, Edward L.
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055439	A2	20030710	WO 2002-US22975	20020718
WO 2003055439	A3	20031204		
W: US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
US 2004241686	A1	20041202	US 2004-484067	20040519
PRIORITY APPLN. INFO.:			US 2001-306250P	P 20010718
			WO 2002-US22975	W 20020718

IT 554478-87-4 554478-88-5
RL: PRP (Properties)
(unclaimed protein sequence; recombinant antigen from **Her2/neu** for tumor immunotherapy)

RN 554478-87-4 HCAPLUS

CN 1: PN: WO03055439 SEQID: 1 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
51 QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIHNPQ VRQVPLQRLR
101 IVRGQTQLFED NYALAVLDNG DPLNNTTPVT GASPGLREL QLRSLTEILK
151 GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
201 GSRGWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRTY FGASCVTACP
301 YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
351 REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
401 ETLEEITGYL YISAWPDSL PDLVFNQNLQV IRGRILHNGA YSLTLQGLGI
451 SWLGLRSLRE LGSGLALIIH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
501 EDECVGEGLA CHQLCARGHC WPGPPTQCVN CSQFLRGQEC VEECRVLQGL
551 PREYVNARHC LPCHPECQPP NGSVTCFGPE ADQCVACAHY KDPPFCVARC
601 PSGVKPDLSY MLIWKFPEDE GACQPCPINC THSCVDLDDK GCPAEQRASP
651 LTSIISAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRRRL LQETELVEPL
701 TPGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL
801 MPYGCLLDHV RENRGRGSGQ DLLNWCMQIA KGMSYLEDVR LVHRDLAARN
851 VLVKSPNHVK ITDFGLARLL DIDETEHYHAD GGKVPKWKMA LESILRRRFT
901 HQSDVWSYGV TVWELMTFGA KPYDGI PARE IPDLLEKGER LPQPPICTID
951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL
1001 DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS
1051 STRSGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAGLQGS
1101 LPTHGDSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP
1151 SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
1201 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG
1251 LDVPV

RN 554478-88-5 HCAPLUS

CN 2: PN: WO03055439 SEQID: 2 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MELAAWCRWG FLLALLPPGI AGTQVCTGTD MKLRLPASPE THLDMLRHLY
51 QGCQVVQGNL ELTYVPANAS LSFLQDIQEV QGYMLIAHNPQ VKRVPLQRLR
101 IVRGQTQLFED KYALAVLDNR DPQDNVAAS PGRTPEGLRE LQLRSLTEIL
151 KGGVLIRGNP QLCYQDMVLW KDVFRKNNQL APVDIDTNRS RACPPCAPAC
201 KDNHCWGES EDCQILTGTI CTSGCARCKG RLPTDCCHEQ CAAGCTGPKH
251 SDCLACLHFN HSGICELHCP ALVTYNTDTF ESMHNPEGRTY TFGASCVTTC
301 PYNYLSTEVG SCTLVCPNN QEVTAEDGTQ RCEKCSKPCA RVCYGLGMEH
351 LRGARAITSD NVQEFDGCKK IFGSLAFLPE SFDGDPSSGI APLRPEQLQV
401 FETLEEITGY LYISAWPDSL RDLVFNQNL IIRGRILHDG AYSLTLQGLG
451 IHSGLRSLR ELGSGALIIH RNAHLCFVHT VPWDQLFRNP HQALLHSGNR

501 PEEDLCVSSG LVCNSLCAHG HCWGPPTQC VNCSHFLRGQ ECVEECRVWK
 551 GLPREYVSDK RCLPCHPECQ PQNSSETCFG SEADQCAACA HYKDSSSCVA
 601 RCPSGVKPDL SYMPIWKYPD EEGICQPCPI NCTHSCVDLD ERGCPAEQRA
 651 SPVTFIATV VGVLLFLILV VVVGILIKRR RQKIRKYTMR RLLQETELVE
 701 PLTPSGAMPN QAQMRILKET ELRKVKVLGS GAFGTVYKGI WIPDGENVKI
 751 PVAIKVLREN TSPKANKEIL DEAYVMAGVG SPYVSRLGI CLTSTVQLVT
 801 QLMPIYGCLLD HVREHRGRLG SQDLLNWCVQ IAKGMSYLED VRLVHRDLAA
 851 RNVLVKSPNH VKITDFGLAR LLDIDETEHY ADGGKVPIKW MALESILRRR
 901 FTHQSDVWSY GVTWELMTF GAKPYDGIPA REIPDLLEKG ERLPQPPICT
 951 IDVYMIMVKC WMIDSECRPR FRELVSEFSR MARDPQRFVV IQNEDLGPSS
 1001 PMDSTFYRSL LEDDDMGDLV DAEYLVPQQ GFFSPDPTPG TGSTAHRRHR
 1051 SSSTRSGGGE LTLGLEPSEE GPPRSPLAPS EGAGSDVFDG DLAMGVTKGL
 1101 QSLSPHDLSP LQRYSEDPTL PLPPETDGYV APLACSPQPE YVNQSEVQPQ
 1151 PPLTPEGPLP PVRPAGATLE RPKTLSPGKN GVVKDVFAFG GAVENPEYLV
 1201 PREGTASPPH PSPAFSPAFD NLYYWDQNSS EQGPPPSNFE GTPAENPEY
 1251 LGLDVPV

L4 ANSWER 27 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:511090 HCAPLUS

DOCUMENT NUMBER: 139:90411

TITLE: Method and related composition employing nanostructures

INVENTOR(S): Stirbl, Robert C.; Snead, Malcolm L.; Xu, Jimmy; Vitetta, Ellen S.; Wilk, Peter J.

PATENT ASSIGNEE(S): Wilk Patent Development Corporation, USA

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053357	A2	20030703	WO 2002-US40678	20021218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003171257	A1	20030911	US 2002-322892	20021218
PRIORITY APPLN. INFO.:			US 2001-342894P	P 20011219
IT 553717-73-0, Protein (human gene Erb b fragment) RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (amino acid sequence; method and related composition employing nanostructures)				
RN 553717-73-0 HCAPLUS				
CN Protein (human gene Erb b fragment) (9CI) (CA INDEX NAME)				

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
 51 QGCQVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIHNP VRQVPLQRLR
 101 IVRGTLQFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK
 151 GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK

201 GSRWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
 251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
 301 YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
 351 REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPAANTA PLQPEQLQVF
 401 ETLEEITGYL YISAWPDSL PDLVFNQNLQV IRGRILHNGA YSLTLQGLGI
 451 SWGLRLSLRE LGSGLALIIH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
 501 EDECVGEGLA CHQLCARGHC WPGPPTQCVN CSQFLRGQEC VEECRVLQGL
 551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
 601 PSGVKPDLIS MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
 651 LTSIVSAWVV GILLVVVLGW VVFGILIKRR QQKIRKYTMR RLLQETELVE
 701 PLTPSGAMPN QAQMRILKET ELRKVKVLGS GAFGTVYKGI WIPDGENVKI
 751 PVAIKVLREN TSPKANKEIL DEAYVMAGVG SPYVSRLGI CLTSTVQLVT
 801 QLMPYGCILL HVRENRRGLG SQDLLNWCML IAKGMSYLED VRLVHRDLAA
 851 RNVLVKSPNH VKITDFGLAR LLDIDETEHY ADGGKVPIKW MALESILRRR
 901 FTHQSDVWSY GVTWELMTF GAKPYDGIPA REIPDLLEKG ERLPQPPICT
 951 IDVYMIMVKC WMIDSECRPR FRELVSFESR MARDPQRFVW VIQNEGLGPA
 1001 SPLDSTFYRS LLEDDDMGDL VDAEEYLVPQ QGFFCPDPAP GAGGMVHHRH
 1051 RSSSTRSGGG DLTGLGLEPSE EEAPRSPLAP SEGAGSDVFD GDLGMGAAGK
 1101 LQSLPTHDP S PLQRYSEDPT VPLPSETDGY VAPLTCSPQP EYVNQPDVRP
 1151 QPPSPREGPL PAARPAGATL ERAKTLSPGK NGVVKDVFAF GGAVENPEYL
 1201 TPQGGAPQHP HPPPAFSPAF DNLYYWDQDP PERGAPPSTF KGTPTAENPE
 1251 YLGLDVPV

L4 ANSWER 28 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:242529 HCAPLUS

DOCUMENT NUMBER: 138:265625

TITLE: Protein and cDNA sequences of human hepatocellular carcinoma associated protein (HCAP) and **ErbB**-2, and use for treating HCAP associated diseases

INVENTOR(S): Reiss, Yuval; Alroy, Iris

PATENT ASSIGNEE(S): Proteologics, Inc., USA

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025228	A1	20030327	WO 2002-US29577	20020918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005004017	A1	20050106	US 2004-490002	20040826
PRIORITY APPLN. INFO.:			US 2001-323210P	P 20010918
			US 2001-332350P	P 20011109
			WO 2002-US29577	W 20020918

IT 503079-16-1P, Neu (receptor) (human)

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
 PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(amino acid sequence; protein and cDNA sequences of human
hepatocellular carcinoma associated protein (HCAP) and **ErbB-
2**, and use for treating HCAP associated diseases)

RN 503079-16-1 HCAPLUS
CN Neu (receptor) (human) (9CI) (CA INDEX NAME)

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
51 QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIHNPQ VRQVPLQRLR
101 IVRGTLQFED NYALAVLDNG DPLNNTTPVT GASPGLREL QLRSLTEILK
151 GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
201 GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
301 YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
351 REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
401 ETLEEITGYL YISAWPDSL PDLVFQNLQV IRGRILHNGA YSLTLQGLGI
451 SWLGLRSLRE LGSGLALHH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
501 EDECVGEGLA CHQLCARGHC WPGPPTQCVN CSQFLRGQEC VEECRVLQGL
551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
601 PSGVKPDLSE MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
651 LTSIIISAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRL LQETELVEPL
701 TPSGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL
801 MPYGCLLDHV RENRGLGSQ DLLNWCQIA KGMSYLEDVR LVHRDLAARN
851 VLVKSPNHVK ITDFGLARLL DIDETEHYHAD GGKVPKWMA LESILRRRFT
901 HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID
951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL
1001 DSTFYRSLLE DDDMGDLVDA EEYLVPPQGF FCPDPAPGAG GMVHHRHRSS
1051 STRSGGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAGKGLQS
1101 LPTHDPSPPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPH
1151 PPPAFSPAFA NLYYWDQDPP ERGAPPSTFK GTPTAENPEY LGLDVPV

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:117855 HCAPLUS

DOCUMENT NUMBER: 138:164059

TITLE: HER3 variant polypeptides and methods for identifying
compounds which bind the heregulin binding site of
HER3

INVENTOR(S): Singer, Elizabeth; Landgraf, Ralf; Slamon, Dennis J.;
Eisenberg, David

PATENT ASSIGNEE(S): The Regents of the University of California, USA

SOURCE: PCT Int. Appl., 137 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011897	A1	20030213	WO 2002-US23963	20020729
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

US 2003143568 A1 20030731 US 2002-207498 20020729
PRIORITY APPLN. INFO.: US 2001-308341P P 20010727
IT 497121-55-8

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(HER3 variant polypeptides and methods for identifying compds. which
bind the heregulin binding site of HER3)

RN 497121-55-8 HCAPLUS

CN Epidermal growth factor receptor 2 (human) (9CI) (CA INDEX NAME)

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
51 QGCQVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR
101 IVRGTLQFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK
151 GGVLIQNRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
201 GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
301 YNYLSTDVGS CTLCVPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
351 REVRVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
401 ETLEEITGYL YISAWPDSL P DLSVFQNLQV IRGRILHNGA YSLTLQGLGI
451 SWLGLRSLRE LGSGLALIIH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
501 EDECVGEGLA CHQLCARGHC WPGPGTQCVN CSQFLRGQEC VEECRVLQGL
551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
601 PSGVKPDL SY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
651 LTSIVSAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRR LQETELVEPL
701 TPSGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL
801 MPYGCLLDHV RENRGRIGSQ DLLNWCMIQIA KGMSYLEDVR LVHRDLAARN
851 VLVKSPNHVK ITDFGLARLL DIDETEHAD GKVPKIKWMA LESILRRRFT
901 HQSDVWSYGV TVWELMTFGA KPYDGI PARE IPDLLEKGER LPQPPICTID
951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL
1001 DSTFYRSLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS
1051 STRSGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAGLQGS
1101 LPTHDPSPQL RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP
1151 SPREGPLPAA RPAGATLERA KTLSPGKNGV VKDVFAFGGA VENPEYLTPO
1201 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG
1251 LDVPV

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:76882 HCAPLUS

DOCUMENT NUMBER: 138:135820

TITLE: Epitope sequences derived from tumor-associated
antigens for use in diagnosis and vaccines

INVENTOR(S): Simard, John J. L.; Diamond, David C.; Liu, Liping;
Xie, Zhidong

PATENT ASSIGNEE(S): CTL Immunotherapies Corp., USA; Mannkind Corp.

SOURCE: PCT Int. Appl., 239 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2003008537	A2	20030130	WO 2002-US10189	20020329
WO 2003008537	C2	20040219		

W: AU

PRIORITY APPLN. INFO.: US 2001-282211P P 20010406
US 2001-337017P P 20011107
US 2002-363210P P 20020307

IT 481152-11-8, GenBank AAA75493
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; epitope sequences derived from tumor-associated antigens for use in diagnosis and vaccines)

RN 481152-11-8 HCAPLUS

CN Neu (receptor) (human clone lambda-HER2-436) (9CI) (CA INDEX NAME)

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
51 QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIHNO VRQVPLQRLR
101 IVRGTLQFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK
151 GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
201 GSRWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRTY FGASCVTACP
301 YNYLSTDVGS CTLVCPHNG EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
351 REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
401 ETLEEITGYL YISAWPDSL PDLVFNQNLQV IRGRILHNGA YSLTLQGLGI
451 SWLGLRSLRE LGSGGLALHH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
501 EDECVGEGLA CHQLCARGHC WPGGPTQCVN CSQFLRGQEC VEECRVLQGL
551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
601 PSGVKPDLSY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
651 LTSIVSAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRR LQETELVEPL
701 TPSGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLGICL TSTVQLVTQL
801 MPYGCCLLDHV RENRGRGSG DLLNWCMIQIA KGMSYLEDVR LVHRDLAARN
851 VLVKSPNHVK ITDFGLARLL DIDETEHAD GGKVPKWKMA LESILRRRFT
901 HQSDVWSYGV TVWELMTFGA KPYDGI PARE IPDLLEKGER LPQPPICTID
951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL
1001 DSTFYRSLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS
1051 STRSGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAGLQS
1101 LPTHDPSPLO RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP
1151 SPREGPLPAA RPAGATLERA KTLSPGKNGV VKDVFAFGGA VENPEYLTPO
1201 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG
1251 LDVPV

L4 ANSWER 31 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:793764 HCAPLUS

DOCUMENT NUMBER: 137:309478

TITLE: anticancer vaccines comprising epitopes of tumor or neovasculature antigen

INVENTOR(S): Simard, John J. L.; Diamond, David C.; Liu, Liping; Xie, Zhidong

PATENT ASSIGNEE(S): CTL Immunotherapies Corp., USA; Mannkind Corporation

SOURCE: PCT Int. Appl., 352 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2002081646 A2 20021017 WO 2002-US11101 20020404
 WO 2002081646 A3 20030717
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
 GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2442386 AA 20021017 CA 2002-2442386 20020404
 EP 1383528 A2 20040128 EP 2002-723804 20020404
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 PRIORITY APPLN. INFO.: US 2001-282211P P 20010406
 US 2001-337017P P 20011107
 US 2002-363210P P 20020307
 WO 2002-US11101 W 20020404
 IT 473024-74-7, Neu (receptor) (human)
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP
 (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (amino acid sequence; anticancer vaccines comprising epitopes of tumor
 or neovasculature antigen)
 RN 473024-74-7 HCAPLUS
 CN Neu (receptor) (human) (9CI) (CA INDEX NAME)

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
 51 QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIHNO VRQVPLQRLR
 101 IVRGTLQFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK
 151 GGVLIQRNPO LCVQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
 201 GSRWGESSE DCQSLTRTV AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
 251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRTY FGASCVTACP
 301 YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
 351 REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
 401 ETLEEITGYL YISAWPDSL PDLVFNQNLQV IRGRILHNGA YSLTLQGLGI
 451 SWGLRLSLRE LGSGLALHH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
 501 EDECVGEGLA CHQLCARGHC WPGPPTQCVN CSQFLRGQEC VEECRVLQGL
 551 PREYVNARHC LPCHPECQPO NGSVTCFGPE ADQCVACAHY KDPPFCVARC
 601 PSGVKPDLVS MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
 651 LTSIVSAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRL LQETELVEPL
 701 TPGSAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
 751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLGICL TSTVQLVTQL
 801 MPYGCLLDHV RENRGRGSG DLLNWCQIA KGMSYLEDVR LVHRDLAARN
 851 VLVKSPNHVK ITDFGLARLL DIDETEHAD GGVPIKWMA LESILRRRFT
 901 HQSDVVSYGV TVWELMTFGA KPYDGI PARE IPDLLEKGER LPQPPICTID
 951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL
 1001 DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS
 1051 STRSGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAGLQS
 1101 LPTHDPSPLO RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQP
 1151 SPREGPLPAA RPAGATLERA KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
 1201 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYL
 1251 LDVPV

L4 ANSWER 32 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:556375 HCAPLUS
 DOCUMENT NUMBER: 137:184131
 TITLE: Phage versus phagemid libraries for generation of



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 33 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:391571 HCAPLUS

DOCUMENT NUMBER: 136:384974

TITLE: Mutated antigen variants and encoding polynucleotides for inducing cell-mediated immune responses and treating cancer, autoimmune disease and infection

INVENTOR(S): Mincheff, Milcho S.; Loukinov, Dmitri I.; Zoubak, Seguei

PATENT ASSIGNEE(S): American Foundation for Biological Research, Inc., USA

SOURCE: PCT Int. Appl., 146 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040059	A2	20020523	WO 2001-US45626	20011101
WO 2002040059	A3	20030912		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,

UG, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002039441 A5 20020527 AU 2002-39441 20011101
 PRIORITY APPLN. INFO.: US 2000-704232 A 20001101
 WO 2001-US45626 W 20011101
 IT 427909-78-2DP, Neu (receptor) (human), deletion variants
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
 PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (amino acid sequence; mutated antigen variants and encoding
 polynucleotides for inducing cell-mediated immune responses and
 treating cancer, autoimmune disease and infection)
 RN 427909-78-2 HCAPLUS
 CN Neu (receptor) (human) (9CI) (CA INDEX NAME)

SEQ 1 MRLPASPETH LDMLRHLYQG CQVVQGNLEL TYLPTNASLS FLQDIQEVQG
 51 YVLIAHNQVR QVPLQRLRIV RGTQLFEDNY ALAVLDNGDP LNNTTPVTGA
 101 SPGGLRELQL RSLTEILKGG VLIQRNPQLC YQDTILWKDI FHKNNQLALT
 151 LIDTNRSRAC HPCSPMCKGS RCWGESSEDC QSLTRTVCAG GCARCKGPLP
 201 TDCCHEQCAA GCTGPKHSDC LACLHFNHSG ICELHCPALV TYNTDTFESM
 251 PNPEGRYTFG ASCVTACPYN YLSTDVGSCT LVCPLHNQEV TAEDGTQRCE
 301 KCSKPCARVC YGLGMEHLRE VRAVTSANIQ EFAGCKKIFG SLAFLPESFD
 351 GDPASNTAPL QPEQLQVFET LEEITGYLYI SAWPDSLPLD SVFQNLQVIR
 401 GRILHNGAYS LTLQGLGISW LGLRSLRELG SGLALIHNT HLFCVHTVPW
 451 DQLFRNPHQA LLHTANRPED ECVGEGLACH QLCARGHCWG PGPTQCVNCS
 501 QFLRGQECVE ECRVLQGLPR EYVNARHCLP CHPECQPQNG SVTCFGPEAD
 551 QCVACAHYKD PPFCVARCPS GVKPDLSEMP IWKFPDEEGA CQPCPINCTH
 601 SCVDLDDKGC PAEQRASPLT SIVSAVVGIL LVVVLGVVFG ILIKRRQQKI
 651 RKYTMRRLLQ ETELVEPLTP SGAMPNQAQM RILKETELRK VKVLGSGAFG
 701 TVYKGIWIPD GENVKIPVAI KVLRENTSPK ANKEILDEAY VMAGVGSPYV
 751 SRLLGICLTS TVQLVTQLMP YGCLLDHVRE NRGRIGSDDL LNWCQMIAKG
 801 MSYLEDVRLV HRDLAARNVL VKSPNHVKIT DFGLARLLDI DETEYHADGG
 851 KVPKIMWALE SILRRRFTHQ SDVWSYGVTV WELMTFGAKP YDGIPAREIP
 901 DLLEKGERLP QPPICTIDVY MIMVKCWMID SECRPRFREL VSEFSRMARD
 951 PQRFVVIQNE DLGPASPLDS TFYRSLEDD DMGDLVDAEE YLVPQQGFFC
 1001 PDPAPGAGGM VHHRHRSST RSGGGDLTLG LEPSEEEAPR SPLAPSEGAG
 1051 SDVFDGDLGM GAAKGLQSLP THDPSPLQRY SEDPTVPLPS ETDGYVAPLT
 1101 CSPQPEYVNG PDVRPQPPSP REGPLPAARP AGATLERAKT LSPGKNGVVK
 1151 DVFAFGGAVE NPEYLTPQGG AAPQPHPPPA FSPAFDNLYY WDQDPPERGA
 1201 PPSTFKGTPT AENPEYLGLD VPV

L4 ANSWER 34 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:332053 HCAPLUS
 DOCUMENT NUMBER: 136:354178
 TITLE: Novel therapeutic vaccine formulations comprising
 microparticles of weak immunogenic antigen and
 chitosan
 INVENTOR(S): Beier, Anne Mette; Gautam, Anand; Mouritsen, Soren
 PATENT ASSIGNEE(S): Pharmexa A/S, Den.
 SOURCE: PCT Int. Appl., 97 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034287	A2	20020502	WO 2001-DK705	20011026
WO 2002034287	A3	20030116		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002010407	A5	20020506	AU 2002-10407	20011026
US 2004037840	A1	20040226	US 2001-984092	20011026
PRIORITY APPLN. INFO.:				
			DK 2000-1606	A 20001027
			US 2000-245166P	P 20001103
			DK 2001-936	A 20010618
			WO 2001-DK705	W 20011026
IT	421042-21-9, Neu (receptor) (human)			
	RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(amino acid sequence; novel therapeutic vaccine formulations comprising microparticles of weak immunogenic antigen and chitosan)			
RN	421042-21-9 HCAPLUS			
CN	Neu (receptor) (human) (9CI) (CA INDEX NAME)			

```

SEQ      1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
      51 QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIHNPQ VRQVPLQRLR
     101 IVRGTLQFED NYALAVLDNG DPLNNTTPVT GASPGLREL QLRSLTEILK
     151 GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
     201 GSRGWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
     251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
     301 YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
     351 REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
     401 ETLEEITGYL YISAWPDSL PDLVFQNLQV IRGRILHNGA YSLTLQGLGI
     451 SWLGLRSLRE LGSGLALIH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
     501 EDECVGEGLA CHQLCARGHC WPGPPTQCVN CSQFLRGQEC VEECRVLQGL
     551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
     601 PSGVKPDLSE MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
     651 LTSIVSAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRL LQETELVEPL
     701 TPSGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
     751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL
     801 MPYGCLLDHV RENRGRGSGQ DLLNWCMIQA KGMSYLEDVR LVHRDLAARN
     851 VLVKSPNHVK ITDFGLARLL DIDETEHAD GGVPIKWMA LESILRRRFT
     901 HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID
     951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL
    1001 DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS
    1051 STRSGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAGLQS
    1101 LPTHDPSPQL RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP
    1151 SPREGPLPAA RPAGATLERA KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
    1201 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG
    1251 LDVPV

```

L4 ANSWER 35 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:142876 HCAPLUS
 DOCUMENT NUMBER: 136:195271
 TITLE: Compositions and methods for the diagnosis of

Her-2/neu-associated
malignancies and therapy with **Her-2**
/**neu** protein or DNA vaccines

INVENTOR(S) : Hand-Zimmermann, Susan; Cheever, Martin A.; Foy, Teresa M.; Lodes, Michael J.; Kalos, Michael D.; McNeill, Patricia D.; Vedvick, Thomas S.

PATENT ASSIGNEE(S) : Corixa Corporation, USA

SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014503	A2	20020221	WO 2001-US41733	20010814
WO 2002014503	A3	20030918		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2419533	AA	20020221	CA 2001-2419533	20010814
AU 2001095008	A5	20020225	AU 2001-95008	20010814
US 2002193329	A1	20021219	US 2001-930125	20010814
EP 1366153	A2	20031203	EP 2001-975714	20010814
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
BR 2001013235	A	20040608	BR 2001-13235	20010814
JP 2004522412	T2	20040729	JP 2002-519631	20010814
NO 2003000714	A	20030411	NO 2003-714	20030214
PRIORITY APPLN. INFO.:			US 2000-225152P	P 20000814
			US 2000-236428P	P 20000928
			US 2001-270520P	P 20010221
			WO 2001-US41733	W 20010814
IT 400616-62-8				
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (amino acid sequence; compns. and methods for the diagnosis of Her-2/neu -associated malignancies and therapy with Her-2/neu protein or DNA vaccines)				
RN 400616-62-8 HCAPLUS				
CN L-Phenylalanine, L- α -glutamyl-L- α -glutamyl-L-tyrosyl-L-leucyl-L-valyl-L-prolyl-L-glutamyl-L-glutamylglycyl- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



IT 400795-12-2 400795-17-7 400795-18-8

400795-19-9 400795-20-2

RL: PRP (Properties)

(unclaimed protein sequence; compns. and methods for the diagnosis of
Her-2/neu-associated malignancies and therapy
 with **Her-2/neu** protein or DNA vaccines)

RN 400795-12-2 HCAPLUS

CN 2: PN: WO0214503 SEQID: 2 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
 51 QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIHNPQ VRQVPLQRLR
 101 IVRGTLQFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK
 151 GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
 201 GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
 251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
 301 YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
 351 REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
 401 ETLEEITGYL YISAWPDSL PDLVFNQNLQV IRGRILHNGA YSLTLQGLGI
 451 SWLGLRSLRE LGSGGLALHH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
 501 EDECVGEGLA CHQLCARGHC WPGPTQCVN CSQFLRGQEC VEECRVLQGL
 551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC

601 PSGVKPDL SY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
 651 LTSIIISAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRRRL LQETELVEPL
 701 TPSGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
 751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL
 801 MPYGCLLDHV RENRGRGSGQ DLLNWCMIQA KGMSYLEDVR LVHRDLAARN
 851 VLVKSPNHVK ITDFGLARLL DIDETEHAD GGKVPKWMMA LESILRRRFT
 901 HQSDVWSYGV TWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID
 951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL
 1001 DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS
 1051 STRSGGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAGLQS
 1101 LPTHDPSPQL RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP
 1151 SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
 1201 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYL
 1251 LDVPV

RN 400795-17-7 HCAPLUS

CN 7: PN: WO0214503 SEQID: 8 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MKRRQKIRK YTMRRLLQET ELVEPLTPSG AMPNQAQMRI LKETELRKVK
 51 VLGSAGFTV YKGIWIPDGE NVKIPVAIKV LRENTSPKAN KEILDEAYVM
 101 AGVGSPYVSR LLGICLTSTV QLVTQLMPYG CLLDHVREN RGRGSGDLLN
 151 WCMQIAKGMS YLEDVRLVHR DLAARNVLVK SPNHVKITDF GLARLLDIDE
 201 TEYHADGGKV PIKWMALSI LRRRFTHQSD VWSYGVTVWE LMTFGAKPYD
 251 GIPAREIPDL LEKGERLPQP PICTIDVYMI MVKCMIDSE CRPRFRELVS
 301 EFSRMARDPQ RFVVIQNE DL GPASPLDSTF YRSLLLEDDDM GDLVDAEEYL
 351 VPQQGFFCPD PAPGAGGMVH HRHRSSSTRS GGGDLTLGLE PSEEEAPRSP
 401 LAPSEGAGSD VFDGDLGMGA AKGLQSLPTH DPSPLQRYSE DPTVPLPSET
 451 DGYVAPLTCS PQPEYVNQPD VRPQPPSPRE GPLPAARPAG ATLERPKTLS
 501 PGKNGVVKDV FAFGGAVENP EYLTPQGGAA PQPHPPPAFS PAFDNLYYWD
 551 QDPPERGAPP STFKGTPAE NPEYLGLDVP VHHHHHH

RN 400795-18-8 HCAPLUS

CN 8: PN: WO0214503 SEQID: 9 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MKRRQKIRK YTMRRLLQET ELVEPLTPSG AMPNQAQMRI LKETELRKVK
 51 VLGSAGFTV YKGIWIPDGE NVKIPVAIKV LRENTSPKAN KEILDEAYVM
 101 AGVGSPYVSR LLGICLTSTV QLVTQLMPYG CLLDHVREN RGRGSGDLLN
 151 WCMQIAKGMS YLEDVRLVHR DLAARNVLVK SPNHVKITDF GLARLLDIDE
 201 TEYHADGGKV PIKWMALSI LRRRFTHQSD VWSYGVTVWE LMTFGAKPYD
 251 GIPAREIPDL LEKGERLPQP PICTIDVYMI MVKCMIDSE CRPRFRELVS
 301 EFSRMARDPQ RFVVIQNE DL GPASPLDSTF YRSLLLEDDDM GDLVDAEEYL
 351 VPQQGFFCPD PAPGAGGMVH HRHRSSSTRS GGGDLTLGLE PSEEEAPRSP
 401 LAPSEGAGSD VFDGDLGMGA AKGLQSLPTH DPSPLQRYSE DPTVPLPSET
 451 DGYVAPLTCS PQPEYVNQPD VRPQPPSPRE GPLPAARPAG ATLERPKTLS
 501 PGKNGVVKDV FAFGGAVENP EYLTPQGGAA PQPHPPPAFS PAFDNLYYWD
 551 QDPPERGAPP STFKGTPAE NPEYLGLDVP VLE

RN 400795-19-9 HCAPLUS

CN 9: PN: WO0214503 SEQID: 10 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MQHHHHHHHK RRQKIRKYT MRRLQETEL VEPLTPSGAM PNQAQMRIK
 51 ETELKRVKVL GSGAGFTVYK GIWIPDGENV KIPVAIKVLR ENTSPKANKE
 101 ILDEAYVMAG VGSPYVSRLL GICLTSTVQL VTQLMPYGCL LDHVRENRR
 151 LGSQDLLNWC MQIAKGMSYL EDVRLVHRDL AARNVLVKSP NHVKITDFGL

201 ARLLDIDETE YHADGGKVPI KWMALESILR RRFTHQSDVW SYGVTWVWELM
 251 TFGAKPYDGI PAREIPDLLE KGERLPQPP I CTIDVYMIMV KCWMIDSECR
 301 PRFRELVSEF SRMARDPQRF VVIQNE DLGP ASPLDSTFYR SLLEDDDDMGD
 351 LVDAEEYLVP QQGFFCPDPA PGAGGMVHHR HRSSSTRSGG GDLTLGLEPS
 401 EEEAPRSPLA PSEGAGSDVF DGD LGMGA AK GLQSLPTHDP SPLQRYSEDP
 451 TVPLPSETDG YVAPLTCSPQ PEYVNQPDVR PQPPSPREGP LPAARPAGAT
 501 LERP KTLSPG KNGVVKDVFA FGGAVENPEY LTPQGGAAPQ PHPPPAFSPA
 551 FDNLYYWDQD PPERGAPPST FKGTPTAENP EYLGLDVPV

RN 400795-20-2 HCAPLUS
 CN 10: PN: WO0214503 SEQID: 11 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MGHHHHHHHH SSGALDDDDK KRRQQKIRKY TMRLLQETE LVEPLTPSGA
 51 MPNQAQMRIL KETELRKVKV LGSGAFGT VY KGIWIPDGEN VKIPVAIKVL
 101 RENTSPKANK EILDEAYVMA GVGSPYVSRL LGICLTSTVQ LVTQLMPYGC
 151 LLDHVREN RG RLGSQDLLNW CMQIAKGMSY LEDVRLVHRD LAARNVLVKS
 201 PNHVKITDFG LARLLDIDET EYHADGGKVP IKWMALESIL RRRFTHQSDV
 251 WSYGVTWVWEL MTFGAKPYDG IPAREIPDLL EKGERLPQPP ICTIDVYMIM
 301 VKCWMIDSEC RPRFRELVSE FSRMARDPQR FVVIQNE DLG PASPLDSTFY
 351 RSLLLEDDDMG DLVDAEEYL V PQQGFFCPDP APGAGGMVHH RHRSSSTRSG
 401 GGDLTLGLEP SEEEAPRSPL APSEGAGSDV FDGDLGMGAA KGLQSLPTH
 451 PSPLQRYSED PTVPLPSETD GYVAPLTCSP QPEYVNQPDV RPQPPSPREG
 501 PLPAARPAGA TLERPKTLSP GKNVVKDVFA FGGAVENPE YLTPQGGAAP
 551 QPHPPPAFSP AFDNLYYWDQ DPPERGAPPS TFKGTPTAEN PEYLGLDVPV

L4 ANSWER 36 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:142537 HCAPLUS
 DOCUMENT NUMBER: 136:194236
 TITLE: Methods using **Her2/neu** sequences
 for diagnosis and therapy of hematological and
 virus-associated malignancies
 INVENTOR(S): Gaiger, Alexander; Cheever, Martin A.;
 Hand-Zimmermann, Susan
 PATENT ASSIGNEE(S): Corixa Corporation, USA
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013847	A2	20020221	WO 2001-US25408	20010813
WO 2002013847	A3	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001083360	A5	20020225	AU 2001-83360	20010813
US 2003157119	A1	20030821	US 2002-313644	20021204
PRIORITY APPLN. INFO.:			US 2000-638280	A 20000814

US 2000-675904 A 20000928
US 1999-404443 B2 19990922
WO 2001-US25408 W 20010813

IT 400616-62-8

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(her2/neu sequences for diagnosis and therapy of
hematol. and virus-associated malignancies)

RN 400616-62-8 HCAPLUS


CN L-Phenylalanine, L- α -glutamyl-L- α -glutamyl-L-tyrosyl-L-leucyl-
L-valyl-L-prolyl-L-glutamyl-L-glutamylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 401552-77-0

RL: PRP (Properties)

(unclaimed protein sequence; methods using Her2/neu
sequences for diagnosis and therapy of hematol. and virus-associated
malignancies)

RN 401552-77-0 HCAPLUS

CN 2: PN: WO0213847 SEQID: 2 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
51 QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIHNO VRQVPLQRLR
101 IVRGTQLFED NYALAVLDNG DPLNNTTPVT GASPGLREL QLRSLTEILK
151 GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
201 GSRGWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRTY FGASCVTACP
301 YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
351 REVRVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
401 ETLEEITGYL YISAWPDSL PDLVFNQLQV IRGRILHNGA YSLTLQGLGI
451 SWGLRLSLRE LGSGLALHH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
501 EDECVGGLA CHQLCARGHC WPGGPTQCVN CSQFLRGQEC VEECRVLQGL
551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVAHAH KDPPFCVARC
601 PSGVKPDLSE MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
651 LTSIISAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRR LQETELVEPL
701 TPGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLGICL TSTVQLVTQL
801 MPYGCLLDHV RENRGLGSQ DLLNWCMIQIA KGMSYLEDVR LVHRDLAARN
851 VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPKWMMA LESILRRRFT
901 HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID
951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL
1001 DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS
1051 STRSGGDLT LGLEPSEEEA PRSLAPSEG AGSDVFDGDL GMGAAGLQSL
1101 LPTHDPSPQL RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP
1151 SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
1201 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG
1251 LDVPV

L4 ANSWER 37 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:123077 HCAPLUS
DOCUMENT NUMBER: 136:178974
TITLE: Construction and purification of Her-
2/neu fusion proteins and their use
to inhibit cancer cell growth
INVENTOR(S): Cheever, Martin A.; Gheysen, Dirk
PATENT ASSIGNEE(S): Corixa Corporation, USA; Smithkline Beecham
Biologicals SA
SOURCE: PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012341	A2	20020214	WO 2001-US24283	20010803
WO 2002012341	A3	20030417		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2417915	AA	20020214	CA 2001-2417915	20010803
AU 2001079153	A5	20020218	AU 2001-79153	20010803

EP 1328631 A2 20030723 EP 2001-957404 20010803
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004521609 T2 20040722 JP 2002-518312 20010803
 PRIORITY APPLN. INFO.: US 2000-632507 A 20000803
 WO 2001-US24283 W 20010803

IT 399098-52-3DP, neu (receptor) (human), fusion products
 399098-53-4DP, neu (receptor) (rat), fusion products
 400185-31-1DP, 990-1257-neu (receptor) (human), fusion
 products 400185-32-2DP, 990-1048-neu (receptor)
 (human), fusion products 400185-33-3P 400185-34-4P
 400185-39-9DP, neu (receptor) (mouse), fusion products
 400185-40-2P 400185-42-4P 400185-44-6P
 400185-45-7P 400185-46-8P 400185-47-9P
 400185-48-0P 400185-49-1P 400185-51-5P
 400185-52-6P

RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); PRP
 (Properties); PUR (Purification or recovery); BIOL (Biological study);
 PREP (Preparation)

(amino acid sequence; construction and purification of Her-
 2/neu fusion proteins and their use to inhibit cancer
 cell growth)

RN 399098-52-3 HCAPLUS

CN neu (receptor) (human) (9CI) (CA INDEX NAME)

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
 51 QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIHNNQ VRQVPLQRLR
 101 IVRGTLQFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK
 151 GGVLIQRNPO LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
 201 GSRGWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
 251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
 301 YNYLSTDVSN CTLVCPHNNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
 351 REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
 401 ETLEEITGYL YISAWPDSL P DLSVFQNLQV IRGRILHNGA YSLTLQGLGI
 451 SWLGLRSLRE LGSGLALHH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
 501 EDECVGEGLA CHQLCARGHC WPGPGTQCVN CSQFLRGQEC VEECRVLQGL
 551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARG
 601 PSGVKPDLISY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
 651 LTSIIISAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRR LQETELVEPL
 701 TPGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
 751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLGICL TSTVQLVTQL
 801 MPYGCLLDHV RENRGRLGSQ DLLNWCMIQIA KGMSYLEDVR LVHRDLAARN
 851 VLVKSPNHVK ITDFGLARLL DIDETEHAD GGKVPKWKMA LESILRRRFT
 901 HQSDVWSYGV TWELMTFGA KPYDGI PARE IPDLLEKGER LPQPPICTID
 951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL
 1001 DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRS
 1051 STRSGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAGLQS
 1101 LPTHDPSPLO RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP
 1151 SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
 1201 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG
 1251 LDVPV

RN 399098-53-4 HCAPLUS

CN neu (receptor) (rat) (9CI) (CA INDEX NAME)

SEQ 1 MELAAWCRWG FLLALLPPGI AGTQVCTGTD MKLRLPASPE THLDMLRHLY
 51 QGCQVVQGNL ELTYVPANAS LSFLQDIQEV QGYMLINNNQ VKRVPLQRLR
 101 IVRGTLQFED KYALAVLDNR DPQDNVAAS PGRTPEGLRE QLRSLTEIL
 151 KGGVLIRGNP QLCYQDMVLW KDVFRKNNQL APVDIDTNRS RACPPCAPAC

601	PSGVKPDLSY	MPIWKFPDEE	GACQPCPINC	THSCVDLDDK	GCPAEQRASP
651	LTSQNEDLGP	ASPLDSYFYR	SLLEDDDMGD	LVDAEEYLVP	QQGFFCPDPA
701	PGAGGMVHHR	HRSSSTRSGG	GDLTLGLEPS	EEEAPRSPLA	PSEGAGSDVF
751	DGDLGMGAAG	GLQSLPTHDP	SPLQRYSEDP	TVPLPSETDG	YVAPLTCSPQ
801	PEYVNQPDVR	PQPPSPREGP	LPAARPAGAT	LERPKTLPSPG	KNGVVKDVFA
851	FGGAVENPEY	LTPQGGAAPQ	PHPPPAFSPA	FDNLYYWDQD	PPERGAPPST
901	FKGTPTAENP	EYLGLDVPV			

RN 400185-34-4 HCAPLUS
 CN (1-653)-(990-1048)-neu (receptor) (human) (9CI) (CA INDEX NAME)

SEQ	1	MELAAALCRWG	LLLALLPPGA	ASTQVCTGTD	MKLRLPASPE	THLDMRLRHL
	51	QGCQVQGNL	ELTYLPTNAS	LSFLQDIQEV	QGYVLIHNR	VRQVPLQRLR
	101	IVRGTLQFED	NYALAVLDNG	DPLNNTTPT	GASPGGLREL	QLRSLTEILK
	151	GGVLIQRNPQ	LCYQDTILWK	DIFHKNNQLA	LTLIDTNRSR	ACHPCSPMCK
	201	GSRCWGESSE	DCQSLTRTVC	AGGCARCKGP	LPTDCCHEQC	AAGCTGPKHS
	251	DCLACLHFNH	SGICELHCPA	LVTYNTDTFE	SMPNPEGRYT	FGASCVTACP
	301	YNYLSTDVGS	CTLVCPLHNQ	VCYGLGMEHL	REVRAVTSAN	IQEFAGCKKI
	351	FGSLAFLPES	FDGDPASNTA	PLQPEQLQVF	ETLEEITGYL	YISAWPDSL
	401	DLSVFQNLQV	IRGRILHNGA	YSLTLQGLGI	SWLGLRSLRE	LGSGLALIIH
	451	NTHLCFVHTV	PWDQLFRNPH	QALLHYANRP	EDECVGEGLA	CHQLCARGHC
	501	WGPPTQCVN	CSQFLRGQEC	VEECRVLQGL	PREYVNARHC	LPCHPECQPQ
	551	NGSVTCFGPE	ADQCVACAHY	KDPPFCVARC	PSGVKPDLSY	MPIWKFPDEE
	601	GACQPCPINC	THSCVDLDDK	GCPAEQRASP	LTSQNEDLGP	ASPLDSTFYR
	651	SLLEDDDMGD	LVDAEEYLVP	QQGFFCPDPA	PGAGGMVHHR	HR

RN 400185-39-9 HCAPLUS
 CN neu (receptor) (mouse) (9CI) (CA INDEX NAME)

SEQ	1	MELAAWCRWG	FLLALLSPGA	AGTQVCTGTD	MKLRLPASPE	THLDMRLRHL
	51	QGCQVQGNL	ELTYLPANAS	LSFLQDIQEV	QGYMLIAHNR	VKHVPLQRLR
	101	IVRGTLQFED	KYALAVLDNR	DPLDNVTAA	PGRTPPEGLR	LQLRSLTEIL
	151	KGGVLIIRGNP	QLCYQDMVLW	KDVLRKNNQL	APVMDTNRS	RACPPCAPTC
	201	KDNHCWGESP	EDCQILTGTI	CTSGCARCKG	RLPTDCCHEQ	CAAGCTGPKH
	251	SDCLACLHFN	HSGICELHCP	ALITYNTDTF	ESMLNPEGRY	TFGASCVTTC
	301	PYNYLSTEVG	SCTLVCPNN	QEVTAEDGTQ	RCEKCSKPCA	GVCYGLGMEH
	351	LRGARAITSD	NIQEFAGCKK	IFGSLAFLPE	SFDGNPSSGV	APLKPEHLQV
	401	FETLEEITGY	LYISAWPESF	QDLSVFQNL	VIRGRILHDG	AYSLTLQGLG
	451	IHSLGLRSLR	ELGSGLALIH	RNTHLCFVNT	VPWDQLFRNP	HQALLHSGNR
	501	PEEACGLEGL	VCNSLCARGH	CWGPPTQCV	NCSQFLRGQE	CVVEECRVWKG
	551	LPREYVRGKH	CLPCHPECQP	QNSSETCYGS	EADQCEACAH	YKDSSSCVAR
	601	CPSGVKPDLS	YMPIWKYPDE	EGICQPCPIN	CTHSCVDLDE	RGCPAEQRAS
	651	PVTFIIATVV	GVLLFLIIIV	VIGILIKRRR	QKIRKYTMRR	LLQETELVEP
	701	LTPSGAVPNQ	AQMRILKETE	LRKLKVLGSG	AFGTVYKGIW	IPDGENVKIP
	751	VAIKVLENT	SPKANKEILD	EAYVMAGVGS	PYVSRLLGIC	LTSTVQLVTQ
	801	IMPYGCLLDH	VREHRGRLGS	QDLLNWCQVI	AKGMSYLEEV	RLVHRDLAAR
	851	NVLVKSPNHV	KITDFGLARL	LDIDETEHYA	DGGKVPKWM	ALESILRRRF
	901	THQSDVMSYG	VTWELMTFG	AKPYDGI PAR	EIPDLLEKGE	RLPQPPICTI
	951	DVYMIMVKCW	MIDSECRPRF	RELVSEFSRM	ARDPQRFVVI	QNEDLGPSSP
	1001	MDSTFYRSL	EDDDMGELVD	AEEYLVPQQG	FFSPDPALGT	GSTAHRHRHS
	1051	SSARSGGEL	TGLEPSEEE	PPRSPLAPSE	GAGSDVFDGD	LAVGVTKGLQ
	1101	SLSPHDLSP	QRYSEDP TLP	LPPETDGYVA	PLACSPQPEY	VNQPEVRPQS
	1151	PLTPEGPPPP	IRPAGATLER	PKTLPSPGKNG	VVKDVFAFGG	AVENPEYLAP
	1201	RAGTASQPHP	SPAFSPA FDN	LYYWDQNSSE	QGPPPSTFEG	TPTAENPEYL
	1251	GLDVPV				

RN 400185-40-2 HCAPLUS
 CN (1-653)-(990-1256)-neu (receptor) [990-serine] (mouse) (9CI) (CA INDEX NAME)

SEQ 1 MELAAWCRWG FLLALLSPGA AGTQVCTGTD MKLRLPASPE THLDMLRHLY
 51 QGCQVVQGNL ELTYLPANAS LSFLQDIQEV QGYMLIAHNR VKHVPLQRLR
 101 IVRG TQLFED KYALAVLDNR DPLDNVT TAA PGRTPEGLRE LQLRSLTEIL
 151 KGGVLIRGNP QLCYQDMVLW KDVL RKNNQL APVDMDTNRS RACPPCAPTC
 201 KDNHCWGESP EDCQILTGTI CTSGCARCKG RLPTDCCHEQ CAAGCTGPKH
 251 SDCLACLHFN HSGICELHCP ALITYNTDTF ESMLNPEGRY TFGASCVTTC
 301 PYNYLSTEVEG SCTLVCPNN QEVTAEDGTQ RCEKCSKPCA GVCYGLGMEH
 351 LRGARAITSD NIQEFAGCKK IFGSLAFLPE SFDGNPSSGV APLKPEHLQV
 401 FETLEEITGY LYISAWPESF QDLSVFQNL R VIRGRILHDG AYSLTLQGLG
 451 IHSLGLRSLR ELGSLALIH RNTHLCFVNT VPWDQLFRNP HQALLHSGNR
 501 PEEACGLEGL VCNSLCARGH CWGPGPTQCV NCSQFLRGQE CVEECRVWKG
 551 LPREYVRGKH CLPCHPECQP QNSSETCYGS EADQCEACAH YKDSSSCVAR
 601 CPSGVKPDLS YMPIWKYPDE EGICQPCPIN CTHSCVDLDE RGCPAEQRAS
 651 PVTSQNE DLG PSSPMDSTFY RSLLEDDDMG ELVDAEEYLV PQQGFFSPDP
 701 ALGTGSTAHR RHRSSSARS G GELTLGLEP SEEEPPRSPL APSEGAGSDV
 751 FDGDLAVGVT KGLQSLSPHD LSPLQRYSED PTLPLPPETD GYVAPLACSP
 801 QPEYVNQPEV RPQSPLTPEG PPPPIRPAGA TLERPKTLSP GKNGVVKDVF
 851 AFGGAVENPE YLAPRAGTAS QPHPSPAFSP AFDNLYYWDQ NSSEQGPPPS
 901 TFEGTPTAEN PEYLGLDVPV

RN 400185-42-4 HCAPLUS
 CN (1-653)-(990-1256)-neu (receptor) [990-serine] (mouse) fusion product with ribosomal protein P (synthetic peptide fragment) (9CI) (CA INDEX NAME)

SEQ 1 MELAAWCRWG FLLALLSPGA AGTQVCTGTD MKLRLPASPE THLDMLRHLY
 51 QGCQVVQGNL ELTYLPANAS LSFLQDIQEV QGYMLIAHNR VKHVPLQRLR
 101 IVRG TQLFED KYALAVLDNR DPLDNVT TAA PGRTPEGLRE LQLRSLTEIL
 151 KGGVLIRGNP QLCYQDMVLW KDVL RKNNQL APVDMDTNRS RACPPCAPTC
 201 KDNHCWGESP EDCQILTGTI CTSGCARCKG RLPTDCCHEQ CAAGCTGPKH
 251 SDCLACLHFN HSGICELHCP ALITYNTDTF ESMLNPEGRY TFGASCVTTC
 301 PYNYLSTEVEG SCTLVCPNN QEVTAEDGTQ RCEKCSKPCA GVCYGLGMEH
 351 LRGARAITSD NIQEFAGCKK IFGSLAFLPE SFDGNPSSGV APLKPEHLQV
 401 FETLEEITGY LYISAWPESF QDLSVFQNL R VIRGRILHDG AYSLTLQGLG
 451 IHSLGLRSLR ELGSLALIH RNTHLCFVNT VPWDQLFRNP HQALLHSGNR
 501 PEEACGLEGL VCNSLCARGH CWGPGPTQCV NCSQFLRGQE CVEECRVWKG
 551 LPREYVRGKH CLPCHPECQP QNSSETCYGS EADQCEACAH YKDSSSCVAR
 601 CPSGVKPDLS YMPIWKYPDE EGICQPCPIN CTHSCVDLDE RGCPAEQRAS
 651 PVTSQNE DLG PSSPMDSTFY RSLLEDDDMG ELVDAEEYLV PQQGFFSPDP
 701 ALGTGSTAHR RHRSSSARS G GELTLGLEP SEEEPPRSPL APSEGAGSDV
 751 FDGDLAVGVT KGLQSLSPHD LSPLQRYSED PTLPLPPETD GYVAPLACSP
 801 QPEYVNQPEV RPQSPLTPEG PPPPIRPAGA TLERPKTLSP GKNGVVKDVF
 851 AFGGAVENPE YLAPRAGTAS QPHPSPAFSP AFDNLYYWDQ NSSEQGPPPS
 901 TFEGTPTAEN PEYLGLDVPV GMGALF

RN 400185-44-6 HCAPLUS
 CN 1-653-neu (receptor) (human) fusion protein with 991-1256-neu (receptor) (rat) (9CI) (CA INDEX NAME)

SEQ 1 MELAAWCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
 51 QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIHNR VRQVPLQRLR
 101 IVRG TQLPED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRLSLTEILK

151	GGVLIQRNPQ	LCYQDTILWK	DIFHKNNQLA	LTLIDTNRSR	ACHPCSPMCK
201	GSRCWGESSE	DCQSLTRTV	AGGCARCKGP	LPTDCCHEQC	AAGCTGPKHS
251	DCLACLHFNH	SGICELHCPA	LVTYNTDTFE	SMPNPEGRYT	FGASCVTACP
301	YNYLSTDVGS	CTLVCPLHNQ	EVTAEADGTQR	CEKCSKPCAR	VCYGLGMEHL
351	REVRAVTSAN	IQEFAGCKKI	FGSLAFLPES	FDGDPASNTA	PLQPEQLQVF
401	ETLEEITGYL	YISAWPDSL	DLSVFQNLQV	IRGRILHNGA	YSLTLQGLGI
451	SWLGLRSLRE	LGSGLALIIH	NTHLCFVHTV	PWDQLFRNPH	QALLHTANRP
501	EDECVGEGLA	CHQLCARGHC	WPGPGPTQCVN	CSQFLRGQEC	VEECRVLQGL
551	PREYVNARHC	LPCHPECQPQ	NGSVTCFGPE	ADQCVACAHY	KDPPFCVARC
601	PSGVKPDLSY	MPIWKFPDEE	GACQPCPIN	THSCVDLDDK	GCPAEQRASP
651	LTSQNEDLGP	SSPMDSTFYR	SLLEDDDMGD	LVDAEEYLVP	QQGFFSPDPT
701	PGTGSTAHRR	HRSSSTRSGG	GELTLGLEPS	EEGPPRSPLA	PSEGAGSDVF
751	DGDLAMGVTK	GLQSLSPHDL	SPLQRYSEDP	TLPLPPETDG	YVAPLACSPQ
801	PEYVNVQSEVQ	PQPPLTPEGP	LPPVRPAGAT	LERPKTLSPG	KNGVVKDVFA
851	FGGAVENPEY	LVPREGTASP	PHPSPAFSPA	FDNLYYWDQN	SSEQGPPPSN
901	FEGTPTAENP	EYLGLDV			

RN 400185-45-7 HCAPLUS
 CN 1-714-neu (receptor) (rat) fusion protein with 990-1257-neu (receptor)
 (human) (9CI) (CA INDEX NAME)

SEQ	1	MELAAWCRWG	FLLALLPPGI	AGTQVCTGTD	MKLRLPASPE	THLDMLRHLY
	51	QGCQVVQGNL	ELTYVPANAS	LSFLQDIQEV	QGYMLIAHNQ	VKRVPLQRLR
	101	IVRGTLQFED	KYALAVLDNR	DPQDNVAAST	PGRTPPEGLRE	LQLRSLTEIL
	151	KGGVLIRGNP	QLCYQDMVLW	KDVFRKNNQL	APVDIDTNRS	RACPPCAPAC
	201	KDNHCWGESP	EDCQILTGTI	CTSGCARCKG	RLPTDCCHEQ	CAAGCTGPKH
	251	SDCLACLHFN	HSGICELHCP	ALVTYNTDTF	ESMHNPEGRY	TFGASCVTTC
	301	PYNYLSTEVG	SCTLVCPNN	QEVTAEDGTQ	RCEKCSKPCA	RVCYGLGMEH
	351	LRGARAITSD	NVQEFDGCKK	IFGSLAFLPE	SFDGDPSSGI	APLRPEQLQV
	401	FETLEEITGY	LYISAWPDSL	RDLSVFQNL	IIRGRILHDG	AYSLTLQGLG
	451	IHSLGLRSLR	ELGSGLALIH	RNAHLCFVHT	VPWDQLFRNP	HQALLHSGNR
	501	PEEDCGLEGL	VCNSLCAHGH	CWGPPTQCV	NCSHFLRGQE	CVEECRVWKG
	551	LPREYVSDKR	CLPCHPECQP	QNSSETCFGS	EADQCAACAH	YKDSSSCVAR
	601	CPSGVKPDLS	YMPIWKYPDE	EGICQPCPIN	CTHSCVDLDE	RGCPAEQRAS
	651	PVTQFQEDLG	PASPLDSTFY	RSLLLEDDMG	DLVDAEEYL	PQQGFFCPDP
	701	APGAGGMVHH	RHRSSSTRSG	GGDLTLGLEP	SEEEAPRSPL	APSEGAGSDV
	751	FDGDLGMGAA	KGLQSLPTH	PSPLQRYSED	PTVPLPSETD	GYVAPLTCSP
	801	QPEYVNVQPDV	RPQPPSPREG	PLPAARPAGA	TLERPKTLSP	GKNGVVKDV
	851	AFGGAVENPE	YLTPQGGAAP	QPHPPPAFSP	AFDNLYYWDQ	DPPERGAPPS
	901	TFKGTPTAEN	PEYLGLDVPV			

RN 400185-46-8 HCAPLUS
 CN 1-714-neu (receptor) (rat) fusion protein with 991-1256-neu (receptor)
 (rat) (9CI) (CA INDEX NAME)

SEQ	1	MELAAWCRWG	FLLALLPPGI	AGTQVCTGTD	MKLRLPASPE	THLDMLRHLY
	51	QGCQVVQGNL	ELTYVPANAS	LSFLQDIQEV	QGYMLIAHNQ	VKRVPLQRLR
	101	IVRGTLQFED	KYALAVLDNR	DPQDNVAAST	PGRTPPEGLRE	LQLRSLTEIL
	151	KGGVLIRGNP	QLCYQDMVLW	KDVFRKNNQL	APVDIDTNRS	RACPPCAPAC
	201	KDNHCWGESP	EDCQILTGTI	CTSGCARCKG	RLPTDCCHEQ	CAAGCTGPKH
	251	SDCLACLHFN	HSGICELHCP	ALVTYNTDTF	ESMHNPEGRY	TFGASCVTTC
	301	PYNYLSTEVG	SCTLVCPNN	QEVTAEDGTQ	RCEKCSKPCA	RVCYGLGMEH
	351	LRGARAITSD	NVQEFDGCKK	IFGSLAFLPE	SFDGDPSSGI	APLRPEQLQV
	401	FETLEEITGY	LYISAWPDSL	RDLSVFQNL	IIRGRILHDG	AYSLTLQGLG
	451	IHSLGLRSLR	ELGSGLALIH	RNAHLCFVHT	VPWDQLFRNP	HQALLHSGNR
	501	PEEDCGLEGL	VCNSLCAHGH	CWGPPTQCV	NCSHFLRGQE	CVEECRVWKG
	551	LPREYVSDKR	CLPCHPECQP	QNSSETCFGS	EADQCAACAH	YKDSSSCVAR

601 CPSGVKPDLS YMPIWKYPDE EGICQPCPIN CTHSCVDLDE RGCPAEQRAS
 651 PVTQFQNEGLG PSSPMDSTFY RSLLEDDDMG DLVDAEEYLV PQQGFSPDP
 701 TPGTGSTAHRR RHRSSSTRSG GGELTLGLEP SEEGPPRSPL APSEGAGSDV
 751 FDGDLAMGVT KGLQSLSPHD LSPLQRYSED PTLPLPPETD GYVAPLACSP
 801 QPEYVNQSEV QPQPPLTPEG PLPPVRPAGA TLERPKTLSP GKNGVVKDVF
 851 AFGGAVENPE YLVPREGTAS PPHPSPAFSP AFDNLYYWDQ NSSEQGPPPS
 901 NFEGTPTAEN PEYLGLDV

RN 400185-47-9 HCAPLUS
 CN 1-653-neu (receptor) (human) fusion protein with 991-1049-neu (receptor)
 (rat) (9CI) (CA INDEX NAME)

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
 51 QGCQVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR
 101 IVRGTLQPED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK
 151 GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
 201 GSRWCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
 251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
 301 YNYLSTDVGS CTLCVPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
 351 REVRATSTAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
 401 ETLEEITGYL YISAWPDSL PDLVSFQNLQV IRGRILHNGA YSLTLQGLGI
 451 SWLGLRSLRE LGSGLALIIH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
 501 EDECVGEGLA CHQLCARGHC WPGPGPTQCVN CSQFLRGQEC VEECRVLQGL
 551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
 601 PSGVKPDLSY MPIWKFPDEE GACQPCPIN CTHSCVDLDDK GCPAEQRASP
 651 LTSQNEGLGP SSPMDSTFYR SLLLEDDDMGD LVDAAEYLV PQQGFSPDPT
 701 PGTGSTAHRR HR

RN 400185-48-0 HCAPLUS
 CN 1-714-neu (receptor) (rat) fusion protein with 990-1048-neu (receptor)
 (human) (9CI) (CA INDEX NAME)

SEQ 1 MELAAWCRWG FLLALLPPGI AGTQVCTGTD MKLRLPASPE THLDMLRHLY
 51 QGCQVQGNL ELTYVPANAS LSFLQDIQEV QGYMLIAHNQ VKRVPLQRLR
 101 IVRGTLQFED KYALAVLDNR DPQDNVAAST PGRTPEGLRE LQLRSLTEIL
 151 KGGVLIRGNP QLCYQDMVLW KDVFRKNNQL APVDIDTNRS RACPPCAPAC
 201 KDNHCWGESP EDCQILTGTI CTSGCARCKG RLPTDCCHEQ CAAGCTGPKH
 251 SDCLACLHFN HSGICELHCP ALVTYNTDTF ESMHNPEGRY TFGASCVTTC
 301 PYNLSTEVG SCTLVCPNN QEVTAEDGTQ RCEKCSKPCA RVCYGLGMEH
 351 LRGAIRITSD NVQEFDGCKK IFGSLAFLPE SFDGDPSSGI APLRPEQLQV
 401 FETLEEITGY LYISAWPDSL RDLVSFQNL IIRGRILHDG AYSLTLQGLG
 451 IHSGLRSLR ELGSLALIIH RNAHLCFVHT VPDQLFRNP HQALLHSGNR
 501 PEEDCGLEGL VCNSLCAHGH CWGPGPTQCV NCSHFLRGQE CVEECRVWKG
 551 LPREYVSDKR CLPCHPECQP QNSSETCFG S EADQCAACAH YKDSSSCVAR
 601 CPSGVKPDLS YMPIWKYPDE EGICQPCPIN CTHSCVDLDE RGCPAEQRAS
 651 PVTQFQNEGLG PASPLDSTFY RSLLEDDDMG DLVDAEEYLV PQQGFSPDPT
 701 APGAGGMVHH RHR

RN 400185-49-1 HCAPLUS
 CN 1-714-neu (receptor) (rat) fusion protein with 991-1049-neu (receptor)
 (rat) (9CI) (CA INDEX NAME)

SEQ 1 MELAAWCRWG FLLALLPPGI AGTQVCTGTD MKLRLPASPE THLDMLRHLY
 51 QGCQVQGNL ELTYVPANAS LSFLQDIQEV QGYMLIAHNQ VKRVPLQRLR

451 IHSLGLRSLR ELGSLGLALIH RNAHLCFVHT VPWDQLFRNP HQALLHSGNR
501 PEEDCGLEGL VCNSLCAHGH CWGPGPTQCV NCSHFLRGQE CVEECRVWKG
551 LPREYVSDKR CLPCHPECQP QNSSETCFG S EADQCAACAH YKDSSSCVAR
601 CPSGVKPDLS YMPIWKYPDE EGICQPCPIN CTHSCVDLDE RGCPAEQRAS
651 PVTFRRRRLT PSGAMPNQAQ MRILKETELR KVKVLGSGAF GTVYKGIWIP
701 DGENVKIPVA IKVLRENTSP KANKEILDEA YVMAGVGSPY VSRLLGICLT
751 STVQLVTQLM PYGCLLDHVR EHRGRLGSQD LLNWCVQIAK GMSYLEDVRL
801 VHRDLAARNV LVKSPNHVKI TDFGLARLLD IDETEYHADG GKVPIKWMAL
851 ESILRRRFTH QSDVWSYGVV VWELMTFGAK PYDGI PAREI PDLLEKGERL
901 PQPPICTIDV YMIMVKCWM I DSECRPRFRE LVSEFSRMAR DPQRFVVIQN
951 EDLGPSSPMD STFYRSLLED DDMGDLVDAE EYLVPQQGFF SPDPTPGTGS
1001 TAHRHRSSS TRSGGELTL GLEPSEEGPP RSPLAPSEGA GSDVFDGDLA
1051 MGVTKGLQSL SPHDLSPLQR YSEDPTLPLP PETDGYVAPL ACSPQPEYVN
1101 QSEVQPQPL TPEGPLPPVR PAGATLERPK TLSPGKNGVV KDVFAFGGAV
1151 ENPEYLVPRE GTASPPHPSP AFSPAFDNLY YWDQNSSEQG PPPSNFEGTP
1201 TAENPEYLGL DVPV

L4 ANSWER 38 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:693348 HCAPLUS

DOCUMENT NUMBER: 135:271875

TITLE: Peptides related to an **HER2** receptor
epitope, polynucleotides encoding the peptides, and
their use in immunomodulation

INVENTOR(S): Nicolette, Charles A.

PATENT ASSIGNEE(S): Genzyme Corporation, USA

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068677	A2	20010920	WO 2001-US40328	20010316
WO 2001068677	A3	20020510		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6528060	B1	20030304	US 2000-527487	20000316
CA 2402721	AA	20010920	CA 2001-2402721	20010316
EP 1287034	A2	20030305	EP 2001-927416	20010316
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004505607	T2	20040226	JP 2001-567767	20010316
US 2003147905	A1	20030807	US 2003-338730	20030108
PRIORITY APPLN. INFO.:			US 2000-527487	A 20000316
			WO 2001-US40328	W 20010316

IT 362539-68-2 362539-69-3 362539-70-6

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; peptides related to **HER2** receptor
epitope, polynucleotides encoding peptides, and their use in
immunomodulation)

RN 362539-68-2 HCAPLUS
 CN Neu (receptor) [774-phenylalanine,775-leucine,776-tyrosine,777-tyrosine,779-threonine,780-threonine] (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 362539-69-3 HCAPLUS
 CN Neu (receptor) [774-phenylalanine,775-leucine,776-phenylalanine,777-threonine,778-proline,779-threonine,780-isoleucine] (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 362539-70-6 HCAPLUS
 CN Neu (receptor) [774-phenylalanine,775-leucine,776-phenylalanine,777-aspartic acid,778-proline,779-threonine,780-threonine] (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 264179-59-1, Neu (receptor) (human)
 RL: PRP (Properties)
 (unclaimed protein sequence; peptides related to an **HER2** receptor epitope, polynucleotides encoding the peptides, and their use in immunomodulation)

RN 264179-59-1 HCAPLUS
 CN Neu (receptor) (human) (9CI) (CA INDEX NAME)

```

SEQ      1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLV
      51 QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIHNO VRQVPLQRLR
     101 IVRGTLQFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK
     151 GGVLIQRNPO LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
     201 GSRWGEGSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
     251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
     301 YNYLSTDVGS CTLCVPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
     351 REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
     401 ETLEEITGYL YISAWPDSL PDLVFNQLQV IRGRILHNGA YSLTLQGLGI
     451 SWGLRLSLRE LGSGLALHH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
     501 EDECVGEGLA CHQLCARGHC WPGGPTQCVN CSQFLRGQEC VEECRVLQGL
     551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
     601 PSGVKPDLSE MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
     651 LTSIVSAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRL LQETELVEPL
     701 TPSGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
     751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLGICL TSTVQLVTQL
     801 MPYGCLLDHV RENRGRGSGQ DLLNWCQIA KGMSYLEDVR LVHRDLAARN
     851 VLVKSPNHVK ITDFGLARLL DIDETEHAD GGKVPIKWMA LESILRRRFT
     901 HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID
     951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL
    1001 DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS
    1051 STRSGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAGLQS
    1101 LPTHDPSPLO RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP
    1151 SPREGPLPAA RPAGATLERA KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
    1201 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG
    1251 LDVPV
  
```

L4 ANSWER 39 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:545837 HCAPLUS

DOCUMENT NUMBER: 135:132425

TITLE: Compounds and methods for prevention and treatment of **her-2/neu** associated malignancies using antigen-presenting cells producing an immune response to **her-2/**

INVENTOR(S): neu
Cheever, Martin A.; Hand-Zimmermann, Susan
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053463	A2	20010726	WO 2001-US1850	20010119
WO 2001053463	A3	20020214		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2398102	AA	20010726	CA 2001-2398102	20010119
US 2002039573	A1	20020404	US 2001-765973	20010119
EP 1252294	A2	20021030	EP 2001-906603	20010119
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

PRIORITY APPLN. INFO.: US 2000-177545P P 20000121
WO 2001-US1850 W 20010119

IT 351908-16-2P, 676-1255-Neu receptor (human)
RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation); PROC (Process)
(amino acid sequence, antigen-presenting cells expressing immunogenic fragment; **her-2/neu** associated malignancies
treatment with antigen-presenting cells producing immune response to **her-2/neu**)

RN 351908-16-2 HCAPLUS
CN 676-1255-Neu receptor (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 100630-38-4, Receptor (human MKN-7 cell gene c-erbB2 precursor protein moiety reduced)
RL: PRP (Properties)
(unclaimed protein sequence; compds. and methods for prevention and treatment of **her-2/neu** associated malignancies using antigen-presenting cells producing an immune response to **her-2/neu**)

RN 100630-38-4 HCAPLUS
CN Receptor (human MKN-7 cell gene c-erbB2 precursor protein moiety reduced) (9CI) (CA INDEX NAME)

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
51 QGCQVVGQNL ELTYLPTNAS LSFLQDIQEV QGYVLIHNO VRQVPLQRLR
101 IVRGTLQFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK
151 GGVLQIRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
201 GSRWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
301 YNYLSTDVGS CTLVCPHNO EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
351 REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGPASNTA PLQPEQLQVF
401 ETLEEITGYL YISAWPDSLP DLSVFQNLQV IRGRILHNGA YSLTLQGLGI

451 SWGLRLSLRE LGSGLALIIH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
 501 EDECVGEGLA CHQLCARGHC WPGPTQCVN CSQFLRGQEC VEECRVLQGL
 551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
 601 PSGVKPDLISY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
 651 LTSIIISAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRRLLQETELVEPL
 701 TPSGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
 751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL
 801 MPYGCLLDHV RENRGRGSGQ DLLNWCMQIA KGMSYLEDVR LVHRDLAARN
 851 VLVKSPNHVK ITDFGLARLL DIDETEHAD GGKVPIKWMA LESILRRRFT
 901 HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID
 951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL
 1001 DSTFYRSLLE DDDMGDLVDA EEYLVPQGGF FCPDPAPGAG GMVHHRHRSS
 1051 STRSGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVDFDGL GMGAAGLQSS
 1101 LPTHDPSPLO RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP
 1151 SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
 1201 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG
 1251 LDVPV

L4 ANSWER 40 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:489634 HCAPLUS

DOCUMENT NUMBER: 135:88013

TITLE: Mouse gene **Her-2/neu** (c-
erbB2) polynucleotides and polypeptides, and
 uses thereof in pharmaceutical compositions and/or
 vaccines for treatment of breast cancer

INVENTOR(S): Spies, A. Gregory

PATENT ASSIGNEE(S): Corixa Corp., USA

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001048205	A2	20010705	WO 2000-US35648	20001229
WO 2001048205	A3	20020207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-474382 A 19991229

IT 286969-79-7P

RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified);
 PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (amino acid sequence; mouse gene **Her-2/neu**
 (c-**erbB2**) polypeptide, its sequence, recombinant production,
 biol. and therapeutic uses, including use in pharmaceutical compns.
 and/or vaccines for treatment of breast cancer)

RN 286969-79-7 HCAPLUS

CN 13: PN: WO0044899 SEQID: 14 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MELAAWCRWG FLLALLSPGA AGTQVCTGTD MKLRLPASPE THLDMLRHLY
51 QGCQVQGNL ELTYLPANAS LSFLQDIQEV QGYMLIAHNR VKHVPLQRLR
101 IVRGTQLFED KYALAVLDNR DPLDNVTTAA PGRTPEGLRE LQLRSLTEIL
151 KGGVLIRGNP QLCYQDMVLW KDVLRKNNQL APVDMDTNRS RACPPCAPTC
201 KDNHCWGESP EDCQILTGTI CTSGCARCKG RLPTDCCHEQ CAAGCTGPKH
251 SDCLACLHFN HSGICELHCP ALITYNTDTF ESMLNPEGRY TFGASCVTTC
301 PYNYLSTEVG SCTLVCPNN QEVTAEDGTQ RCEKCSKPCA GVCYGLGMEH
351 LRGARAITSD NIQEFAGCKK IFGSLAFLPE SFDGNPSSGV APLKPEHLQV
401 FETLEEITGY LYISAWPESF QDLSVFQNL RIRGRILHDG AYSLTLQGLG
451 IHSGLRLSLR ELGSGLALIH RNTHLCFVNT VPWDQLFRNP HQALLHSGNR
501 PEEACGLEGL VCNSLCARGH CWGPGPTQCV NCSQFLRGQE CVEECRVWKG
551 LPREYVRGKH CLPCHPECQP QNSSETCYGS EADQCEACAH YKDSSSCVAR
601 CPSGVKPDLS YMPIWKYPDE EGICQPCPIN CTHSCVDLDE RGCPAEQRAS
651 PVTFIIATVV GVLLFLIIVV VIGILIKRRR QKIRKYTMRR LLQETELVEP
701 LTPSGAVPNQ AQMRILKETE LRKLKVLGSG AFGTVYKGIW IPDGENVKIP
751 VAIKVLRENT SPKANKEILD EAYVMAGVGS PYVSRLLGIC LTSTVQLVTQ
801 LMPYGCLLDH VREHRGRLGS QDLLNWCVQI AKGMSYLEEV RLVHRDLAAR
851 NVLVKSPNHV KITDFGLARL LDIDETEHYHA DGGKVPIKWM ALESILRRRF
901 THQSDVWSYG VTWELMTFG AKPYDGIPAR EIPDLLEKGE RLPQPPICTI
951 DVYIMIMVKCW MIDSECRPRF RELVSEFSRM ARDPQRFVVI QNEDLGPSSP
1001 MDSTFYRSL EDDDMGELVD AEEYLVPQQG FFSPDPALGT GSTAHRHRS
1051 SSARSGGEL TLGLEPSEEL PPRSPLAPSE GAGSDVFDGD LAVGVTKGLQ
1101 SLSPHDLSP QRYSEDPTLP LPPETDGYVA PLACSPQPEY VNQPEVRQS
1151 PLTPEGPPPP IRPAGATLER PKTLSPGKNG VVKDVFAFGG AVENPEYLAP
1201 RAGTASQPHP SPAFSPAFDN LYYWDQNSSE QGPPPSTFEG TPTAENPEYL
1251 GLDVPV

L4 ANSWER 41 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:434885 HCAPLUS
DOCUMENT NUMBER: 135:60155
TITLE: Inducing cellular immune responses to **HER2/**
neu using peptide and nucleic acid
compositions
INVENTOR(S): Fikes, John; Sette, Alessandro; Sidney, John;
Southwood, Scott; Chesnut, Robert; Celis, Esteban;
Keogh, Elissa
PATENT ASSIGNEE(S): Epimmune Inc., USA
SOURCE: PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001041787	A1	20010614	WO 2000-US33591	20001211
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2393738	AA	20010614	CA 2000-2393738	20001211
EP 1239866	A1	20020918	EP 2000-984214	20001211
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

JP 2003530083 T2 20031014 JP 2001-543131 20001211
US 2004018971 A1 20040129 US 2002-149138 20021024
US 2004121946 A9 20040624
PRIORITY APPLN. INFO.: US 1999-458299 A 19991210
WO 2000-US33591 W 20001211

IT 345380-31-6

RL: PRP (Properties)

(unclaimed sequence; inducing cellular immune responses to **HER2**
/**neu** using peptide and nucleic acid compns.)

RN 345380-31-6 HCAPLUS

CN 1: PN: WO0141787 PAGE: 15 unclaimed sequence (9CI) (CA INDEX NAME)

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
51 QGCQWVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIHNO VRQVPLQRLR
101 IVRGTLQFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK
151 GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
201 GSRGWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
251 DCLACLFHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
301 YNYLSTDVGS CTLCVPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
351 REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
401 ETLEEITGYL YISAWPDSL PDLVFQNLQV IRGRILHNGA YSLTLQGLGI
451 SWLGLRSLRE LGSLGALIIH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
501 EDECVGEGLA CHQLCARGHC WPGGPTQCVN CSQFLRGQEC VEECRVLQGL
551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
601 PSGVKPDLSE MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
651 LTSIIISAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRR LQETELVEPL
701 TPSGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLIGICL TSTVQLVTQL
801 MPYGCLLDHV RENRGRGSGQ DLLNWCMQIA KGMSYLEDVR LVHRDLAARN
851 VLVKSPNHVK ITDFGLARLL DIDETEHAD GGVPIKWM LESILRRRFT
901 HQSDVWSYGV TWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID
951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL
1001 DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS
1051 STRSGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAGLQGS
1101 LPTHDPSPLO RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP
1151 SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
1201 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG
1251 LDVPV

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 42 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:535278 HCAPLUS

DOCUMENT NUMBER: 133:148720

TITLE: Antigenic deletion derivatives of the **Her-2/neu** protein for use in vaccines
against breast cancer

INVENTOR(S): Cheever, Martin A.; Gheysen, Dirk

PATENT ASSIGNEE(S): Corixa Corporation, USA; Smithkline Beecham

SOURCE: PCT Int. Appl., 128 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044899	A1	20000803	WO 2000-US2164	20000128

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
 MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2361009	AA	20000803	CA 2000-2361009	20000128
EP 1147190	A1	20011024	EP 2000-905800	20000128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200102191	T2	20011221	TR 2001-200102191	20000128
BR 2000007840	A	20020122	BR 2000-7840	20000128
JP 2002535004	T2	20021022	JP 2000-596141	20000128
NZ 513062	A	20031031	NZ 2000-513062	20000128
US 2002177567	A1	20021128	US 2001-854356	20010509
ZA 2001006179	A	20021028	ZA 2001-6179	20010726
NO 2001003701	A	20010928	NO 2001-3701	20010727
PRIORITY APPLN. INFO.:			US 1999-117976P	P 19990129
			US 2000-493480	A3 20000128
			WO 2000-US2164	W 20000128

IT **286968-95-4P 286968-98-7DP**, 990-1257-**Neu**
 (receptor) (human), fusion products **286968-99-8P**
287105-76-4DP, 990-1255-**Neu** (receptor) (human), fusion
 products
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic
 use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (amino acid sequence, antigenicity of; antigenic deletion derivs. of
Her-2/neu protein for use in vaccines
 against breast cancer)
 RN 286968-95-4 HCAPLUS
 CN 1-653-neu (receptor) (human) fusion protein with 990-1255-neu (receptor)
 (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 286968-98-7 HCAPLUS
 CN 990-1257-neu (receptor) (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 286968-99-8 HCAPLUS
 CN 1-653-neu (receptor) (human) fusion protein with 990-1048-neu (receptor)
 (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 287105-76-4 HCAPLUS
 CN 990-1255-neu (receptor) (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **100630-38-4**, Receptor (human MKN-7 cell gene c-**erbB2**
 precursor protein moiety reduced) **286969-75-3**
286969-79-7
 RL: PRP (Properties)
 (unclaimed protein sequence; antigenic deletion derivs. of the
Her-2/neu protein for use in vaccines
 against breast cancer)
 RN 100630-38-4 HCAPLUS
 CN Receptor (human MKN-7 cell gene c-**erbB2** precursor protein moiety reduced)
 (9CI) (CA INDEX NAME)

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLV

51 QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR
 101 IVRGTLQFED NYALAVLDNG DPLNNTTPVT GASPGLREL QLRSLTEILK
 151 GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
 201 GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
 251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRTY FGASCVTACP
 301 YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
 351 REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
 401 ETLEEITGYL YISAWPDSL PDLVSVFQNLQV IRGRILHNGA YSLTLQGLGI
 451 SWLGLRSLRE LGSGGLALHH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
 501 EDECVGEGLA CHQLCARGHC WPGPGPTQCVN CSQFLRGQEC VEECRVLQGL
 551 PREYVNRHSC LPCHPECQPP NGSVTCFGPE ADQCVACAHY KDPPFCVARC
 601 PSYGKPLDLY MPIWKFPDEE GACQPCPIN THSCVDLDDK GCPAEQRASP
 651 LTSIIISAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRR LQETELVEPL
 701 TPGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
 751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL
 801 MPYGCLLDHV RENRGRGSG DLLNWCMIQA KGMSYLEDVR LVHRDLAARN
 851 VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPKWM LESILRRRFT
 901 HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID
 951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL
 1001 DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRS
 1051 STRSGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAGLQS
 1101 LPTHDPSPPL RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQP
 1151 SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPO
 1201 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG
 1251 LDVPV

RN 286969-75-3 HCAPLUS
 CN 2: PN: WO0044899 SEQID: 2 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MELAAWCRWG FLLALLPPGI AGTQVCTGTD MKLRLPASPE THLDMLRHL
 51 QGCQVVQGNL ELTYVPANAS LSFLQDIQEV QGYMLIAHNQ VKRVPLQRLR
 101 IVRGTLQFED KYALAVLDNR DPQDNVAAS PGRTPPEGLRE LQLRSLTEIL
 151 KGGVLIRGNP QLCYQDMVLW KDVFRKNNQL APVDIDTNRS RACPPCAPAC
 201 KDNHCWGESP EDCQILTGTI CTSGCARCKG RLPTDCCHEQ CAAGCTGPKH
 251 SDCLACLHFN HSGICELHCP ALVTYNTDTF ESMHNPEGRTY TFGASCVTTC
 301 PYNYLSTEVG SCTLVCPNN QEVTAEDGTQ RCEKCSKPCA RVCYGLGMEH
 351 LRGARAITSD NVQEFDGCKK IFGSLAFLPE SFDGDPSSGI APLRPEQLQV
 401 FETLEEITGY LYISAWPDSL RDLVSVFQNL IIRGRILHDG AYSLTLQGLG
 451 IHSGLRSLR ELGSGGLALH RNAHLCFVHT VPWDQLFRNP HQALLHSGNR
 501 PEEDCGLEGL VCNLSCAHGH CWGPGPTQCV NCSHFLRGQE CVEECRVWKG
 551 LPREYVSDKR CLPCHPECQP QNSSETCFGES EADQCAACAH YKSSSCVAR
 601 EGICQPCPIN CTHSCVDLDE RGCPEQRAS PVTFIATVV GVLLFLILV
 651 VVGILIKRRR QKIRKYTMRR LLQETELVEP LTPSGAMPNQ AQMRILKETE
 701 LRKVKVLGSG AFGTVYKGIW IPDGENVKIP VAIKVLRENT SPKANKEILD
 751 EAYVMAGVGS PYVSRLLGIC LTSTVQLVTQ LMPYGCLLDH VREHRGRLGS
 801 QDLLNWCVQI AKGMSYLEDV RLVHRDLAAR NVLVKSPNHV KITDFGLARL
 851 LDIDETEYHA DGGKVPKWM ALESILRRRF THQSDVWSYG VTVWELMTFG
 901 AKPYDGIPAR EIPDLLEKGE RLPQPPICTI DYMIMVKCW MIDSECRPRF
 951 RELVSEFSRM ARDPQRFVVI QNEDLGPSSP MDSTFYRSL EDDMGDLVD
 1001 AEEYLVPQQG FFSPDPTPGT GSTAHRHRS SSTRSGGGEL TLGLEPSEEG
 1051 PPRSPLAPSE GAGSDVFDG LAMGVTKGLQ SLSPHDLSP QRYSEDPTLP
 1101 LPPETDGYVA PLACSPQPEY VNQSEVQPQ PLTPEGPLPP VRPAGATLER
 1151 PKTLSPGKNG REGTASPPHP SPAFSPAFDN LYYWDQNSSE QGPPPSNFEG
 1201 TPTAENPEYL GLDVPV

RN 286969-79-7 HCAPLUS
 CN 13: PN: WO0044899 SEQID: 14 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MELAAWCRWG FLLALLSPGA AGTQVCTGTD MKLRLPASPE THLDMLRHLY
51 QGCQVVQGNL ELTYLPANAS LSFLQDIQEV QGYMLIAHNR VKHVPLQRLR
101 IVRGTQLFED KYALAVLDNR DPLDNVTTAA PGRTPEGLRE LQLRSLTEIL
151 KGGVLIRGNP QLCYQDMVLW KDVLRKNNQL APVDMDTNRS RACPPCAPTC
201 KDNHCWGESP EDCQILTGTI CTSGCARCKG RLPTDCCHEQ CAAGCTGPKH
251 SDCLACLHFN HSGICELHCP ALITYNTDTF ESMLNPEGRY TFGASCVTTC
301 PYNYLSTEVG SCTLVCPNN QEVTAEDGTQ RCEKCSKPCA GVCYGLGMEH
351 LRGARAITSD NIQEFAGCKK IFGSLAFLPE SFDGNPSSGV APLKPEHLQV
401 FETLEEITGY LYISAWPESF QDLSVFQNL R VIRGRILHDG AYSLTLQGLG
451 IHSGLRLSLR ELGSGLALIH RNTHLCFVNT VPWDQLFRNP HQALLHSGNR
501 PEEACGLEGL VCNSLCARGH CWGPGPTQCV NCSQFLRGQE CVEECRVWKG
551 LPREYVRGKH CLPCHPECQP QNSSETCYGS EADQCEACAH YKDSSSCVAR
601 CPSGVKPDLS YMPIWKYPDE EGICQPCPIN CTHSCVDLDE RGCPAEQRAS
651 PVTFIIATVV GVLLFLIIVV VIGILIKRRR QKIRKYTMRR LLQETELVEP
701 LTPSGAVPNQ AQMRILKETE LRKLKVLGSG AFGTVYKGIW IPDGENVKIP
751 VAIKVLRENT SPKANKEILD EAYVMAGVGS PYVSRLLGIC LTSTVQLVTQ
801 LMPYGCLLDH VREHRGRLGS QDLLNWCVQI AKGMSYLEEV RLVHRDLAAR
851 NVLVKSPNHV KITDFGLARL LDIDETEHYA DGGKVPIKWM ALESILRRRF
901 THQSDVWSYG VTVWELMTFG AKPYDGIPAR EIPDLLEKGE RLPQPPICTI
951 DVYIMIMVKCW MIDSECRPRF RELVSEFSRM ARDPQRFVVI QNEDLGPPSSP
1001 MDSTFYRSL EDDDMGELVD AEEYLVPQQG FFSPDPALGT GSTAHRHRS
1051 SSARSGGGL TLGLEPSEEE PPRSPLAPSE GAGSDVFDGD LAVGVTKGLQ
1101 SLSPHDL SPL QRYSEDPTLP LPPETDGYVA PLACSPQPEY VNQPEVRPQS
1151 PLTPEGPPPP IRPAGATLER PKTLSPGKNG VVKDVFAFGG AVENPEYLAP
1201 RAGTASQPHP SPAFSPAFDN LYYWDQNSSE QGPPPSTFEG TPTAENPEYL
1251 GLDVPV

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 43 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:241473 HCAPLUS

DOCUMENT NUMBER: 132:274827

TITLE: Breast tumor-related human **erbB-2** receptor splice variant and cDNA and methods for inhibition of cell transformation

INVENTOR(S): Muller, William J.; Siegel, Peter M.

PATENT ASSIGNEE(S): McMaster University, Can.

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000020579	A1	20000413	WO 1999-CA912	19991001
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9959636	A1	20000426	AU 1999-59636	19991001
PRIORITY APPLN. INFO.:			US 1998-165192	A 19981002
			WO 1999-CA912	W 19991001

IT 100630-38-4, Receptor (human MKN-7 cell gene c-erbB2 precursor protein moiety reduced)
RL: ADV (Adverse effect, including toxicity); ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; breast tumor-related human erbB-2 receptor splice variant and cDNA and methods for inhibition of cell transformation)
RN 100630-38-4 HCAPLUS
CN Receptor (human MKN-7 cell gene c-erbB2 precursor protein moiety reduced) (9CI) (CA INDEX NAME)

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
51 QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR
101 IVRGTLQFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK
151 GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
201 GSRWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRTY FGASCVTACP
301 YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
351 REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
401 ETLEEITGYL YISAWPDSL PDLVSVFQNLQV IRGRILHNGA YSLTLQGLGI
451 SWGLRLSLRE LGSGLALIIH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
501 EDECVGEGLA CHQLCARGHC WPGPTQCVN CSQFLRGQEC VEECRVLQGL
551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
601 PSGVKPDL SY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
651 LTSIIISAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRR LQETELVEPL
701 TPGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL
801 MPYGCLLDHV RENRGRGSGQ DLLNWCMIQIA KGMSYLEDVR LVHRDLAARN
851 VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPKWM LESILRRRFT
901 HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID
951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL
1001 DSTFYRSLLE DDDMGDLVDA EEYLVPQGGF FCPDPAAGAG GMVHHRHRS
1051 STRSGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAGLQS
1101 LPTHDPSPLO RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP
1151 SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
1201 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG
1251 LDVPV

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 44 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:240985 HCAPLUS

DOCUMENT NUMBER: 132:292701

TITLE: Novel methods for therapeutic vaccination

INVENTOR(S): ~~Steinaa, Lucilla; Mouritsen, Soren; Nielsen, Klaus~~
~~Gregorious; Haaning, Jesper; Leach, Dana; Dalum, Iben;~~
~~Gautam, Anand; Birk, Peter;~~ Karlsson, Gunilla

PATENT ASSIGNEE(S): ~~M & E Biotech A/S, Den.~~

SOURCE: ~~PCT Int. Appl., 220 pp.~~

~~CODEN: BIXXD2~~

DOCUMENT TYPE: ~~Patent~~

LANGUAGE: ~~English~~

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	APPLICATION NO.	DATE
WO 2000020027	A2	20000413	WO 1999-DK525	19991005

WO 2000020027 A3 20001012
W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, CZ, DE, DE, DK, DK, DM, EE, EE, ES, FI, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2345817 AA 20000413 CA 1999-2345817 19991005
AU 9958510 A1 20000426 AU 1999-58510 19991005
AU 751709 B2 20020822
EP 1117421 A2 20010725 EP 1999-945967 19991005
EP 1117421 B1 20040616

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI,
LT, LV, FI, RO

TR 200100936 T2 20010821 TR 2001-200100936 19991005
JP 2002526419 T2 20020820 JP 2000-573386 19991005
EE 200100203 A 20021015 EE 2001-203 19991005
NZ 511055 A 20031031 NZ 1999-511055 19991005
AT 269100 E 20040715 AT 1999-945967 19991005
EP 1502602 A2 20050202 EP 2004-76709 19991005

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL

NO 2001001586 A 20010531 NO 2001-1586 20010328
ZA 2001002603 A 20020930 ZA 2001-2603 20010329
HR 2001000319 A1 20020630 HR 2001-319 20010504
US 2004141958 A1 20040722 US 2003-441779 20030519

PRIORITY APPLN. INFO.:

DK 1998-1261 A 19981005
US 1998-105011P P 19981020
EP 1999-945967 A3 19991005
US 1999-413186 A1 19991005
WO 1999-DK525 W 19991005

IT 264179-59-1, Neu (receptor) (human)

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(amino acid sequence; weak antigens inserted with foreign T cell
epitope as vaccines)

RN 264179-59-1 HCAPLUS

CN Neu (receptor) (human) (9CI) (CA INDEX NAME)

SEQ 1 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY
51 QGCQVVGQNL ELTYLPTNAS LSFLQDIQEV QGYVLIHNPQ VRQVPLQRLR
101 IVRGTQLFED NYALAVLDNG DPLNNTTPVT GASPGLREL QLRSLTEILK
151 GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLDITNRSR ACHPCSPMCK
201 GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
251 DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
301 YNYLSTDVGS CTLCVPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL
351 REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF
401 ETLEEITGYL YISAWPDSLPL DLSVFQNLQV IRGRILHNGA YSLTLQGLGI
451 SWGLRLSLRE LGSLGALIIH NTHLCFVHTV PWDQLFRNPH QALLHTANRP
501 EDECVGEGLA CHQLCARGHC WGPPTQCVN CSQFLRGQEC VEECRVLQGL
551 PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
601 PSGVKPDLSE MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP
651 LTSIVSAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRR LQETELVEPL
701 TPGSGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV
751 AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL
801 MPYGCCLLDHV RENRGRIGSQ DLLNWCQMIA KGMSYLEDVR LVHRDLAARN
851 VLVKSPNHVK ITDFGLARLL DIDETEHAD GKGVPKWM LESILRRRFT
901 HQSDVWSYGV TVWELMTFGA KPYDGI PARE IPDLLEKGER LPQPPICTID
951 VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL